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The need to improve our understanding of vector-specific immunity of HIV vaccine candidates 
was recently highlighted by the STEP trial. This study characterised the humoral and cellular 
immune responses to MVA from a candidate MVA-vectored HIV vaccine in non-human 
primates, and examined the effect of anti-vector immunity on the response to the HIV 
immunogens.  The MVA construct, termed SAAVI-MVA-C, contains multiple genes of HIV-1 
subtype C, and is currently in Phase I clinical trials.  Eight Chacma baboons were vaccinated 
with a DNA-MVA regimen.  Whilst strong and broad anti-HIV responses were generated, we 
investigated whether anti-vector responses may have dampened responses that would 
otherwise have been boosted to even greater levels after successive vaccinations. 
   
Neutralising antibodies to MVA were detected using a MVA-GFP neutralisation assay in all 
animals, as well as binding antibody responses to vaccinia virus envelope proteins A33 and 
B5R, detected by ELISA.  In addition, high magnitude IFN- ELISPOT responses to MVA were 
induced in all animals.  These rose dramatically from a median of 497 SFU/106 PBMC after the 
first MVA vaccination, to 4455 SFU/106 PBMC after the third MVA, given over a year later.  
Responses to the HIV immunogens showed similar magnitudes and kinetics of boosting, 
reaching a median of 4459 SFU/106 PBMC after the third MVA vaccination.  Interestingly, MVA 
responses remained at similar levels 7 months later, whilst HIV responses waned.  There was 
no relationship between MVA-specific responses and HIV-specific responses.  Multiparameter 
flow cytometry was used to detect IFN-, TNF- and IL-2 responses to MVA and HIV, and to 
characterise the differentiation phenotype of memory T-cells, using CD28 and CD95. MVA-
specific CD8+ responses were predominately single function IFN- producing T-cells, while 
lower magnitude CD4+ T-cell responses largely produced TNF- and IL-2.  Greater 
polyfunctionality to the HIV immunogens was evident, which may have been the result of 
earlier recombinant DNA prime vaccinations. Phenotypically there were no differences in 
memory responses to HIV and MVA, with antigen-specific CD4+ T-cells being of the central 
memory phenotype, and CD8+ T-cells showing a more balanced central and effector memory 
profile.  
 
Thus, high magnitude cellular responses were generated to the vector component of a 
candidate MVA-HIV vaccine. This anti-vector immunity, however, did not prevent the 
generation of potent, polyfunctional CD4+ and CD8+ responses to the HIV immunogens 
contained in the vector, or the boosting of these responses after successive vaccinations. 
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AIDS-related death rates are falling worldwide, however HIV remains a global pandemic that 
has claimed the lives of more than 1.3 million people in 2009 in Sub-Saharan Africa alone 
(UNAIDS 2010).  World-wide, there are 32.8 million people living with HIV, and although 
antiretroviral therapy is becoming more widely available, 2.6 million people became newly 
infected with HIV in 2009, 69% of whom were in Sub-Saharan Africa (UNAIDS 2010).  A 
prophylactic HIV vaccine remains the best long-term hope for preventing new infections. 
 
This Chapter discusses challenges for developing an HIV vaccine and progress in preclinical 
and clinical trials of vaccine candidates, with a specific focus on recombinant MVA as a 
vaccine vector and the issue of anti-vector immunity and how this may impact vaccine antigen 
immunity. 
 
1.2 HIV Vaccines 
 
The development of an HIV-1 vaccine presents a huge challenge.  Many highly successful 
vaccines, such as those against smallpox, polio and measles viruses, have been developed, 
leading to eradication of the pathogen or vast reductions in morbidity and mortality from these 
diseases.  Many traditional vaccines have been developed using live attenuated forms of virus, 
inactivated (killed) virus or protein subunits (as reviewed in Girard, 2006).  These approaches 
are not suitable for developing a vaccine against HIV.  Both attenuated and inactivated virus 
have major safety concerns, in that attenuated HIV may mutate and regain its pathogenicity 
after inoculation (as reviewed in Letvin, 2006), and inactivated virus may still contain enough 
live virus to pose a risk (as reviewed in Burgers and Williamson, 2005).  Subunit vaccines have 
been successful for other viruses such as Hepatitis B, and it was initially though that this 
approach may also work for HIV.  However, an HIV envelope subunit vaccine was shown not 
to be protective in two large Phase III efficacy trials in humans (Gilbert et al., 2005; Flynn et al., 
2005).  
 
The major challenges to developing an HIV vaccine include the high genetic variability of HIV-
1, its ability to evade adaptive immune responses, establishment of viral reservoirs resulting in 
latency, the difficulty in generating broadly neutralising antibody responses, unknown 



















HIV-1 is genetically diverse 
 
HIV-1 has an enormous genetic diversity, and consists of four groups (M, N, O and P; Plantier 
et al., 2009; Vallari et al., 2011), of which group M is the most prevalent worldwide and 
consists of nine subtypes/clades and multiple circulating recombinant forms (as reviewed in 
Korber et al., 2009)).  The genetic differences in HIV-1 subtypes result from errors in reverse 
transcription of single stranded RNA into proviral cellular DNA, recombination between two 
genomes, insertions and deletions, as well as gain and loss of glycosylation sites (as reviewed 
in Levy, 2009; Letvin, 2006; Korber et al., 2009).  In addition to the global variability, HIV can 
mutate through intersubtype recombination in individuals that are infected with more than one 
subtype (superinfection) leading to different recombinant HIV strains circulating in one person 
(as reviewed in Korber et al., 2009; Girard, 2006).  In terms of vaccine development, this 
means that any single candidate HIV vaccine will need to be able to induce immune responses 
to multiple subtypes or recombinants to be globally effective (as reviewed in Letvin 2006).   
 
There are several ways in which vaccine designers are attempting to cater for the huge genetic 
diversity of the virus.  One of the ways is by developing polyepitope vaccines, where a large 
number of epitopes based on those commonly recognised in diverse HLA backgrounds are 
expressed by the vaccine. Another method involves the use of central sequences, which 
include consensus, most recent ancestor or centre of tree, which are phylogenetically 
determined (Nickle et al., 2003; Rolland et al., 2007).  More recent approaches involves the 
use of mosaic antigens (as reviewed in Korber et al., 2009), where many variant forms of 
epitopes are included in a “mosaic” to encompass the most common variants of HIV epitopes.  
They have been shown to provide deeper depth and breadth of responses (Santra et al., 
2010), and include not only conserved regions, but conserved and immunologically vulnerable 
regions where immune escape is less likely, due to potential fitness costs (Dahirel et al., 2011). 
 
 HIV evades the adaptive immune system 
 
HIV is able to evade adaptive immune responses, termed viral „escape‟.  HIV has error prone 
reverse trasncriptase which together with the high recombination rate results in viral variants 
that  can resist efficient major histocompatibility complex (MHC) processing, presentation or 
recognition by T-cells (Moore et al., 2002).  In fact, these escape mutations are often in 
response to pressure generated by T-cell responses (Goulder et al., 2004).  The effects of 
escape mutations on HIV are varied.  They can be beneficial to the virus, in that mutated virus 
is no longer recognised by T-cells, they can be deleterious with a fitness cost to the virus, or 

















cell responses were shown to correlate with early control of SIV (Friedrich et al., 2004).  These 
responses quickly selected escape mutations, then lessened or disappeared (Allen et al., 
2004).  Immune escape by HIV also has implications for vaccination, and a recent study of 
participants from the STEP trial has shown that vaccine induced T-cell responses can drive 
HIV to escape, resulting in different viral variants in the vaccinated compared to unvaccinated 
individuals (Rolland et al., 2010).  Not only can escape variants evade recognition by T-cells, 
they can also evade neutralising antibody binding (Wei et al., 2003). 
 
HIV forms latent reservoirs 
 
HIV-1 integrates as a latent proviral DNA into the genome of host cells and provides a 
persistent reservoir of the virus that does not undergo transcription and produces no proteins 
to be presented to immune system (as reviewed in Girard, 2006; Chun et al., 1997).  Latency 
occurs within days to weeks after infection and once established, cannot be eradicated (Finzi 
et al., 1997).  This means that an HIV vaccine would have to generate effective immune 
responses very quickly after infection, at relevant sites of exposure such as genital tissue, to 
prevent latent pool formation.  
 
Neutralising antibodies to HIV 
 
Neutralising antibodies produced by B-cells can potentially protect against infection by blocking 
viral entry into host cells (Gallarda et al., 1992).   In the first two to three weeks of HIV 
infection, binding antibodies against the outer coat protein, known as Env, are generated; 
however these are inefficient and fully neutralising antibodies are only generated much later 
(Gray et al., 2009; Richman et al., 2003).  These early neutralising antibodies only target the 
infecting strain (as reviewed in Montefiori et al., 2007) and it is likely that these autologous 
neutralising antibodies exert pressure on the envelope of HIV, resulting in escape viral variants 
that they are no longer recognised (Moore et al., 2009).  After several years of infection, broad 
antibodies capable of neutralising diverse viral strains develop in only 15 to 25% of infected 
individuals, and these appear too late to prevent or slow disease progression (Binley et al., 
2008; Euler et al., 2010).   
 
Broadly neutralising antibodies have been difficult to induce by vaccination, largely as a result 
of the high genetic variability of the Env capsid protein as well as shielding of antibody binding 
sites by complex glycan shields (Wyatt et al., 1998).  Until 2009, only a handful of broadly 
cross-neutralising antibodies had been isolated from HIV-infected individuals (as reviewed in 

















neutralising antibodies have been identified, revealing a range of neutralisation abilities against 
viral isolates, such as HJ16 showing 40% (Corti et al., 2010), PG9 and PG16 showing 70 to 
80% (Walker et al., 2009; Pejchal et al., 2010) and VRC01, VRC02, VRC03 ranging from 57 to 
90% (Wu et al., 2010; Zhou et al., 2010).  In fact, VRC01 neutralises about 90% of almost 200 
HIV-1 isolates from multiple clades (as reviewed in Poropatich and Sullivan, 2011). The 
discovery of these new broadly cross-neutralizing antibodies has led to structural analysis of 
their molecular features to determine why they are so effective at neutralisation (Pancera et al., 
2010).  Understanding these broadly neutralising antibodies and viral binding sites may assist 
in the design of vaccine immunogens, which  may involve the formation of stabilised Env 
trimers and building conserved neutralisation epitopes onto foreign proteins (as reviewed in 
Barouch, 2008). 
 
Neutralising antibodies delivered passively can protect nonhuman primates from challenge 
intravenously or via the mucosa with SHIV (Mascola et al., 1999; Shibata et al., 1999; Baba et 
al., 2000; Parren et al., 2001).  It has also been shown in humans that the passive transfer of 
broadly neutralising antibodies can delay viral loads returning to high levels after stopping anti-
retroviral treatment in some individuals (Trkola et al., 2005). Thus, preexisting antibodies 
generated by an HIV vaccine could in neutralise and potentially protect against infection.  
Unfortunately, initial clinical efficacy trials developing an HIV vaccine directed against envelope 
protein (gp120), the AIDSVAX trials (discussed further in section 1.2.7) did not elicit 
neutralising antibodies and no protection was observed, and generating neutralising antibodies 
by vaccination remains elusive (Flynn et al., 2005, Gilbert et al., 2005; as reviewed in Korber, 
2009). 
 
There may be a role for non-neutralising antibodies in controlling HIV infection, such as those 
capable of directing antibody dependent cellular cytotoxicity (ADCC; as reviewed in Chung et 
al., 2008).  Cells of the innate immune system such as natural killer cells, neutrophils and 
macrophages can be triggered by ADCC to provide effector functions which may assist in viral 
control (Chung et al., 2011).  High levels of ADCC antibodies have been found in HIV-infected 
individuals and some studies have correlated them with slower progression of HIV infection 
(Nag et al., 2004; Ahmad et al., 2001).  They have also been generated by vaccination in 
humans (Karnasuta et al., 2005).  Passive antibody studies in macaques have confirmed that 
ADCC can reduce viraemia and play a role in protection from disease progression (Hessell et 
al., 2007).  In addition, when induced by vaccination in macaques they have been associated 
with better viral control (Gómez-Román et al., 2005).  These are promising results, however it 
is evident that neutralising antibodies should still be the focus of research, as non-neutralising 


















Design of an HIV-1 vaccine that induces broadly cross-neutralising antibodies or other 
antibody effector mechanisms may be critical for inducing sterilising immunity, although it has 
recently been shown that vaccine induced T-cell responses may also be able to provide 
exceptional control of HIV (Hansen et al., 2011).  An ideal vaccine will probably need to 
generate a combination of humoral and cellular responses.  
 
Unknown correlates of protection 
 
Perhaps the greatest challenge is that we do not know the correlates of protection against HIV 
infection.  Until measurable correlates of protection are defined, there will be little to guide 
vaccine development in both animal or human studies, and the potential effectiveness of 
vaccine concepts and products have to be tested in large, lengthy clinical trials (as reviewed in 
Makedonas and Betts, 2011).  
 
T cell responses have been observed to be associated with the decline in peak viraemia in 
early HIV and SIV infection (Koup et al., 1994; Schmitz et al., 1999) and particularly broad 
Gag-specific T cell responses but not Env-specific responses targeting multiple epitopes have 
been inversely associated with lower viral load and positively correlated with CD4+ counts in 
humans (Kiepiela et al., 2007; Rolland et al., 2008; Zuniga et al., 2006; Geldmacher et al., 
2007).  In vaccinated challenged macaques, high magnitude, broad Gag-specific CD8+ T-cell 
responses have been associated with reductions in peak and setpoint viral loads, decreased 
AIDS-related mortality and a reduction in immune escape variants (Liu et al., 2009; Reece et 
al., 2010).   
 
In addition to producing broad, high magnitude Gag-specific responses, there are various 
functional attributes of a T-cell response that have been correlated with viral control.  
Polyfunctional CD8+ T-cells may the better at viral control.  Betts et al. (2006) showed that 
individuals who control HIV infection have CD8+ T-cells that perform many functions 
simultaneously, including degranulation (CD107a mobilisation), cytokine (IFN-, TNF-α and IL-
2) and chemokine production (MIP-1β).  The production of cytotoxic molecules such as 
perforin and granzyme-B are also important in viral control.  Indeed rapid perforin upregulation 
was the earliest response detected in long-term non-progressors and elite controllers, and 
there was increased T-bet expression, which has been shown to correlate with levels of 
expression of cytolytic molecules, in elite controllers (Hersperger et al., 2010; Hersperger et 
al., 2011).  In addition, the proliferative ability of HIV-specific CD4+ T-cells has also been 

















CD8+ T cells has been inversely correlated with viral load in chronically infected, untreated 
individuals (Rosenberg et al., 1997; Day et al., 2007).  Thus, HIV-specific T cell 
polyfunctionality and proliferative capacity may also be important in control of HIV replication. 
 
The memory differentiation state of T-cell subsets may also be an important factor in viral 
control, not only because function and phenotype are linked, but different subsets have 
different longevity and homing capacities. The amount of central memory HIV-specific CD4+ T-
cells was higher in elite controllers compared to viraemic individuals (Potter et al., 2007; Ladell 
et al., 2008).   On the other hand, fast-acting effector memory T cells at the site of viral 
exposure may also be important for early viral control. Hansen et al. (2009) demonstrated that 
vaccination of macaques with a rhesus CMV vaccine expressing SIV Gag, Rev-Tat-Nef and 
Env protected 4 out of 12 from mucosal challenge with SIV, due to the presence of CD8+ TEM 
cells at the mucosal site. These results were confirmed in a subsequent study of a larger group 
of animals and long-term protection of greater than 1 year was observed (Hansen et al., 2011). 
 
Thus, whilst important features of T cells have been identified as correlating with viral control, it 
is still not clear whether all or some of these features would be required for a successful HIV 
vaccine.  A large effort is being undertaken to identify the correlates of protection in the RV144 
trial, the only clinical trial of an HIV vaccine to date that has demonstrated efficacy in protection 
against HIV infection (Rerks-Ngarm et al., 2009). 
 
Relevance of animal models 
 
Rhesus macaques are widely used as the animal model for HIV infection of humans.  They are 
susceptible to infection with SIV, which shares many features of HIV, and infected animals 
progress to AIDS (albeit more rapidly), mirroring the disease course of HIV infection in humans 
(as reviewed in Koup et al 2011; Mattapallil et al., 2005).  Thus, the non-human primate SIV 
challenge model has been widely used to study HIV vaccine concepts and vaccine candidates.  
Animal models can provide much useful information, however they do need to be interpreted 
with caution, as there are many differences between studies in the way challenges are 
performed.  Challenge viruses may be administered at high doses via intravenous exposure 
(Haigwood et al., 2009), which does not reflect the majority of human sexual exposures to HIV.  
It is likely that more meaningful interpretations can be made if these animals are exposed 
mucosally with repeated low-dose challenges (Keele et al., 2009).  In addition, the challenge 
virus used is often homogenous, using a virus containing sequences very similar to the 
vaccine sequence, which may be more easily controlled than a heterologous challenge, which 

















more accurate to perform a heterologous challenge using a swarm virus such as SIVsmE660, 
with many sequence dissimilarities to vaccine inserts (Watkins et al., 2008).  Illustrating this, 
Wyand et al. (1999) showed that macaques immunised with live-attenuated SIV showed good 
control of viraemia after homologous SIVmac239 challenge, however when animals were 
challenged with heterologous SIVsmE660, there was reduced control of viraemia.  Additionally, 
a recent candidate HIV vaccine showed disappointing results in the STEP trial in humans, 
even though it showed reduced viral loads in homogenously challenged macaques (McElrath 
et al., 2008; Buchbinder et al., 2008; Shiver et al., 2002).  However, when vaccinated 
macaques were challenged with a more stringent heterologous virus, they showed no control 
of viral load, which is more in line with the results generated by the STEP trial (Casimiro et al., 
2005).  Therefore, to provide meaningful information on whether a candidate vaccine should 
be advanced to human trials, monkey studies should be standardised as far as possible in 
terms of the SIV challenge virus, challenge route, challenge dose, species of monkey and 
endpoint measurements (Morgan et al., 2008).   
 
Human efficacy trials of candidate HIV vaccines 
 
Testing candidate vaccines in humans remains the best way to evaluate protection against or 
control of HIV infection.  Thus far, there have been four Phase IIb/III clinical trials that have 
tested the efficacy of candidate HIV vaccines that I will discuss in detail in this section. 
 
The first two phase III clinical trials of an HIV vaccine were initiated in 1998 by VaxGen.  The 
two vaccines consisted of a recombinant form of the glycoprotein-120 (gp120) portion of the 
HIV envelope administered with the adjuvant alum, in an attempt to generate neutralising 
antibodies. The first vaccine, AIDSVax B/B, consisting of two subtype B gp120s, was trialled in 
North America and the Netherlands in 5095 men who have sex with men and 308 
heterosexual women (Gilbert et al., 2005).  The vaccine, which was given in seven 
immunisations over 30 months, elicited a gp-120-specific antibody response, but did not 
neutralise HIV-1 isolates from infected individuals, and showed no protection in an efficacy trial 
with 6.7% of the vaccinated individuals becoming infected versus 7.0% that received the 
placebo (Flynn et al., 2005, Gilbert et al., 2005).  The second vaccine, AIDSVax E/B, 
consisting of subtype E (CRF_AE) and subtype B gp120s, was trialled in 2527 HIV–uninfected 
injection drug users in Thailand.  Similarly, it showed no protection, with 8.4% of vaccine and 
8.3% of placebo participants becoming infected with HIV during the trial (Pitisuttithum et al., 
2006).  The failure of this trial signalled the move away from the „antibody‟ vaccine concept, 
with the acknowledgement of the huge challenges in eliciting neutralising antibodies by 


















The next large clinical trial, a proof of concept phase IIb trial known as the STEP trial, was 
initiated in late 2004 and focused on producing T-cell immune responses.  The rationale for 
inducing T-cell responses by vaccination is discussed in section 1.2.1.  The vaccine consisted 
of a replication-incompetent recombinant adenovirus serotype 5 (rAd5) vector expressing HIV-
1 subtype B Gag, Pol and Nef.  It showed good immunogenicity in non-human primate studies 
and vaccinated animals showed some viral control after challenge with SIVmac239 (Shiver et 
al., 2002; Casimiro et al., 2005; Wilson et al., 2006).  Immunogenicity trials in humans revealed 
that cellular immune responses were elicited in most individuals (Priddy et al., 2008). The 
STEP trial set out to determine whether this vaccine given in a three dose regimen could 
protect from or control viraemia in a total of 3000 individuals from North America, the 
Caribbean, South America and Australia potentially exposed to subtype B HIV strains 
(McElrath et al., 2008).  A similar trial named „Phambili‟, commenced in South Africa. 
 
Robust T-cell responses were detected by IFN- ELISPOT in 77% of vaccinated individuals to 
two or three HIV proteins, with responses greater for Pol than Gag or Nef.  Intracellular 
cytokine staining revealed similar results, with 73% of vaccinated individuals mounting CD8+ 
responses. Lower magnitude CD4+ T-cell responses were detected, in 41% of vaccinated 
individuals (Buchbinder et al., 2008).  Despite the high frequency of responders, 24 of 741 
vaccinated individuals became infected with HIV, versus 21 of 762 individuals that received 
placebo.  Thus, there was no protection against HIV, and viral load set points were not lowered 
in vaccinated individuals that became infected (McElrath et al., 2008; Buchbinder et al., 2008).  
Indeed, there was an increased ri k of HIV infection in vaccinated individuals, and this trial and 
Phambili were halted.  Failur  of this vaccine led to some questioning the potential efficacy of 
T-cell generating vaccines, however it is important to note that vaccinees that became infected 
only recognised two to three epitopes, and that this response may not have been broad 
enough to recognise epitopes in the infecting virus (as reviewed in Wilson and Watkins, 2009; 
Fauci et al., 2008).  Also, the increased risk of HIV infection lasted for 18 months after 
immunisation, and occurred mainly in uncircumcised men with baseline Ad5 titres (Buchbinder 
et al., 2008).  The potential role of anti-vector immunity will be discussed in section 1.3.4.  
Recent results from the Phambili trial showed that the vaccination regimen had no protective 
effect, however there was no association between circumcision and Ad5 titres and lack of 
protection (Gray et al., 2011). 
 
The last efficacy trial was a Phase III trial, RV-144, initiated in Thailand in 2003, in 16 000 men 
and women at heterosexual risk of HIV infection (as reviewed in Vaccari et al, 2010).   The 

















vaccines in a prime-boost strategy.  There were four priming vaccinations of a canarypox-
based- vector known as ALVAC-HIV (vCP1521), and two boosts with VaxGen AIDSVax B/E 
bivalent gp120 subunit vaccine (Rerks-Ngarm et al., 2009).   ALVAC-HIV expressed subtype B 
Gag and Protease, in addition to gp120 clade E, while the AIDSVax is the same gp120 
envelope vaccine that failed in an earlier trial (as reviewed in Vaccari et al., 2010; Gilbert et al., 
2005).  RV144 was the first efficacy trial to show promising results, with 74 out of 8198 placebo 
recipients becoming infected with HIV compared to 51 out of 8197 vaccinated individuals, 
resulting in 31.2% vaccine efficacy (p=0.04; Rerks-Ngarm et al., 2009).  This protective effect 
was seen in the first year following start of vaccination, however the vaccinated individuals that 
acquired infection did not have improved viral control.  The immunogenicity was measured by 
interferon-γ ELISPOT, intracellular cytokine staining, binding antibody to gp120 and 
lymphoproliferation (Rerks-Ngarm et al., 2009). Gag-specific T-cell responses were detected in 
7.6% and Env-specific responses in 11.1% of vaccinated individuals (Rerks-Ngarm et al., 
2009).  Intracellular cytokine staining showed higher CD4+ Env responses in the vaccinated 
versus placebo group, at 34% (Rerks-Ngarm et al., 2009).  On the other hand only moderate 
neutralising activity detected against 3 of 5 tier 1 viruses, suggesting that antibody responses 
other than neutralisation may have contributed to protection (Gilbert et al., 2010).  These data 
provide the first evidence that a vaccine can prevent HIV infection.  The reasons for protection 
provided by this vaccine are being studied to determine immunological correlates of protection. 
 
The AIDSVax, STEP and RV-144 clinical trials show that testing a vaccine candidate in 
humans is the best way of determining vaccine efficacy.  However, human clinical trials are 
complex, expensive and have traditionally followed a sequential approach consisting of phase 
I, phase IIa, phase IIb and phase III studies, which takes years to complete (as reviewed in 
Koup et al., 2011).  Vaccine development needs to be accelerated, possibly by performing 
more stringent macaque studies, focusing on early immune correlates of protection (Watkins et 
al., 2008).  Where possible, priority could be given only to vaccine candidates that show 
control of viraemia in heterologously challenged macaques, eliminating time spent on unlikely 
candidates (as reviewed in Barouch, 2008).  Vaccine induced immune correlates of protection 
need to be determined rapidly so vaccine responses can be tested early in a trial, rather than 
waiting for post-trial analysis. This may require multiple efficacy trials of many different 
candidate vaccines in subjects who are at high risk of HIV infection, allowing more information 
to be gathered quickly and at less expense (Corey et al., 2011).  In addition, trials need to be 
faster, which may require new approaches, such as adaptive trial design, which is an iterative 
approach that allows changes in the study design in response to data being generated during 

















efficacy reduces over time.  This may allow cost effective evaluation of more approaches in a 
shorter amount of time. 
 
In summary, an ideal HIV vaccine should be able to elicit both humoral (broadly neutralising or 
other types of antibodies), as well as broad, strong cellular (CD4+ and CD8+ T-cells), to 
provide long lasting protection.  
 
 
1.3 T-cell vaccines 
 
This literature review will now focus primarily on T-cell vaccines since this is the focus of my 
thesis.  
 
1.3.1 What are the goals of a T-cell based HIV vaccine? 
 
 
An ideal vaccine would elicit sterilising immunity through neutralising antibody production 
(Figure 1.1).  However, as discussed in section 1.2.4, HIV-specific neutralising antibodies have 
not yet been produced by vaccination.  It is thought that a T-cell vaccine could be partially 
effective, resulting in lower virus levels, less destruction of CD4+ T-cells in gut-associated 
lymphoid tissue during the acute phase, and a delay in disease progression (as reviewed in 
Barouch, 2008; Wilson and Watkins, 2009).  This has the potential to reduce secondary 
transmission by herd effect (as reviewed in Girard, 2006; Hanke, 2007.)  It would also be 
beneficial if a vaccine induced immune responses at the genital mucosa to block HIV 
transmission (as reviewed in Shacklett, 2008). 
 
1.3.2 Evidence that a T-cell generating vaccine might control HIV 
 
There is an association between the early appearance of HIV-specific CD8+ T-cells and the 
drop in peak viraemia to setpoint in acute infection both in SIV and HIV (Kuroda et al., 1999; 
Koup et al., 1994; as reviewed in Pantaleo et al., 1996).  Neutralising antibodies are only 
generated later in infection, and thus the cell-mediated rather than antibody responses are 
responsible for early control of viral replication (Koup et al., 1994; Wei et al., 2003; as reviewed 




















Figure 1.1 Goals of an HIV vaccine.  After infection with HIV, replication as determined by viral load 
continues to a point, then drops to setpoint and is partially maintained (dark blue).  An ideal vaccine 
(red) would completely protect against infection, while a vaccine that reduces peak viral replication 
during the acute phase and results in lower or undetectable setpoint viral load during chronic infection 
(light blue) may still be effective in preventing transmission and slowing or preventing disease 
progression (adapted from Wilson & Watkins, 2009 and Barouch, 2008). 
 
 
Consistent with these studies, it has been shown that depletion of CD8+ T-cells by monoclonal 
antibodies led to loss of control of viraemia in macaques infected with SIV (Schmitz et al., 
1999; Okoye et al., 2009).  CD8+ T-cells are efficient killers that are capable of destroying HIV-
infected cells through the Fas/Fas ligand-killing, or death receptor pathway or by the release of 
lytic granules (Poonia et al., 2009; as reviewed in Suni et al., 2005). Fas receptor, also known 
as CD95, is a protein of the TNF receptor family that induces apoptosis on binding Fas ligand.  
This binding sets a chain of events in motion by a system of proteases called caspases within 
the target cell itself and the cascade ends with the destruction of the target.  In addition, CTLs 
have lytic granules containing perforin and granzymes, which induce apoptosis (as reviewed in 
Krenksy and Clayberger, 2005). Besides these molecules, the lytic granules also consist of 
granulysin, which creates holes in the target cell membrane cells. During this process, the 
granule membrane fuses with the cell membrane and releases the killing molecules perforin 


















Several non-human primate studies have shown that T-cell-based vaccines can provide 
immune control or HIV protection.  In early HIV infection, decreased peak viraemia, and 
preserved CD4+ memory T-cells following high dose intravenous and mucosal challenge with 
pathogenic SIVmac239 have been described (Letvin et al., 2006; Liu et al., 2009; Mattapallil et 
al., 2006; Horton et al., 2002; Whitney et al., 2009; Hansen et al., 2009).   Additionally, long-
term control of infection has been shown in vaccinated macaques challenged multiple times 
intra-rectally or intra-vaginally with low dose virus, demonstrating that T-cell vaccination can 
elicit control even in chronic infection (Wilson et al., 2006; Wilson et al., 2009; Manrique et al., 
2011).  In humans, the T-cell vaccine concept was challenged with the failure of the STEP trial, 
where no protection from infection or reduction of viral loads in infected individuals was seen 
(Buchbinder et al., 2008; McElrath et al., 2008). However, the modest protective effect seen in 
the RV-144 Thai trial has provided renewed encouragement that a successful vaccine is 
achievable (Rerks-Ngarm et al., 2009).  Although there was protection from infection in a 
proportion of individuals, there was no reduction in viral loads of those vaccinated individuals 
that did become infected.  It also remains to be determined whether protection was a result of 
innate responses, T-cell responses or antibody-mediated (Rerks-Ngarm et al., 2009). 
 
A potential drawback of generating T-cell responses by vaccination is that SIV/HIV constantly 
mutates to escape epitopes recognised by CD8+ T cells in macaques and humans (Allen et 
al., 2004; Brumme et al., 2008; Goonetilleke et al., 2009).  In fact, suboptimal vaccine 
responses may in theory drive faster escape, which could reduce vaccine efficacy (as 
reviewed in Davenport et al., 2008).  Thus, the ultimate goal of an effective T cell vaccine may 
be to elicit immune responses that are early and target as many of the most conserved 
epitopes as possible, that may limit escape opportunities and inhibit viral replication, or result 
in a fitness cost to the virus, thereby reducing viral replication (as reviewed in Barouch, 2008; 
Reece et al., 2010). 
 
 
1.3.3 T-cell vaccine vectors 
 
Current approaches for the development of HIV vaccines, and indeed several other major 
pathogens, use live viral vectors as “carriers” to deliver HIV antigens, in the hope of stimulating 
potent anti-HIV T cell immune responses which may protect against HIV infection or disease 
(as reviewed in Paris et al., 2010).  Vectors used most commonly include plasmid DNA and 
viruses, especially attenuated adenovirus serotypes and poxviruses (as reviewed in Pantaleo 
et al., 2010).  Viruses have the ability to infect cells where vaccine antigens are expressed and 

















antigens to the immune system and stimulate responses. Viral vectors are being tested as safe 
vaccines for malaria, tuberculosis, HIV, influenza, and various cancers (as reviewed in Brave 
et al., 2006).  These common and other novel vector systems will be discussed in the 




DNA-based vaccines allow direct gene transfer by „naked‟ plasmid DNA, are not virus derived 
and do not rely on other pathogens to deliver antigens (as reviewed in Brave et al., 2007).  
They are relatively cheap to produce, easy to work with and are very stable (as reviewed in 
Hanke, 2001).  In addition, DNA vaccines allow the immune response to focus only on the 
immunogen, as no proteins other than the immunogen are present to be presented to the host 
cells.  Thus, they are safe and have no risk of virulence (MacGregor et al., 1998).  Used alone, 
they generally elicit low magnitude responses of short duration (as reviewed in Lu et al., 1998; 
MacGregor et al., 1998; Graham et al., 2006; Goepfert et al., 2011).  However, they have been 
shown to prime cellular responses to viral candidate vectors well, and are widely used in 
heterologous prime-boost vaccination regimens (as reviewed in Paris et al., 2010; Harari et al., 
2008; Goepfert et al., 2011).  Improved delivery techniques such as electroporation are being 
explored to improve potency of immune responses to DNA vaccines (Otten et al., 2004).  
 
1.3.3.2 Adenovirus vectors 
 
Adenoviruses of the genus Mastadenovirus are medium-sized (90–100 nm), nonenveloped 
icosahedral viruses composed of a nucleocapsid and a double-stranded linear DNA genome of 
36 -38 kb (as reviewed in Brave et al., 2007). In humans, there are 56 accepted human 
adenovirus types (HAdV-1 to 56) in seven species (Human adenovirus A to G; Knipe and 
Howley, 2007).  Adenovirus infections most commonly cause illness of the respiratory system.  
Symptoms of respiratory illness caused by adenovirus infection range from the common cold 
to pneumonia and bronchitis.  Most humans have already been infected with adenoviruses, 
and thus wide-spread pre-existing immunity occurs that may influence vaccine vector 
responses (Mast et al., 2010). 
 
Adenovirus vectors, used alone or in combination with DNA prime vaccines, have been shown 
to be safe and generate strong T-cell responses (Shiver et al., 2002; Priddy et al., 2008).  
Studies in non-human primates have demonstrated induction of potent immune responses 
when using adenovirus type 5 (Ad5) vectors expressing clade B Gag, Pol and Nef, and 

















2006).   In human trials an Ad5 vaccine candidate elicited good cellular immune responses and 
was safe, but failed to protect against HIV infection or to reduce viral loads in infected 
individuals in the STEP trial (Buchbinder et al., 2008).  Potential mechanisms of this will be 
discussed in section 1.3.5.2.   There are also alternative Adenovirus vectors for which there is 
no significant pre-existing immunity in humans, such vector chimeras, other serotypes, and 
nonhuman Ads (as reviewed in Gamble and Matthews, 2010). One of these, Ad26, which is a 
serotype that does not infect humans, is currently in a Phase I clinical trial in a Ad26-Ad5 prime 
boost vaccination regimen (Baden et al., 2009).  In non-human primate studies, this vaccine 
regimen showed control of virus with a 2.4 log reduction in viral set-point and improved survival 
compared to unvaccinated controls, but preliminary results from a Phase I clinical trial indicate 
that it is not as immunogenic in humans (Liu et al., 2009; Matthew Johnson, Keystone 
Symposia, Protection from HIV: Targeted Intervention Strategies (X8), Canada, 2011).   
 
1.3.3.3 Poxvirus vectors 
 
Poxviruses are the largest and most complex of all viruses.   They are enveloped and contain 
complex DNA genomes of up to 360 kb that encode more than 200 genes (as reviewed in 
Brave et al., 2007). They infect a wide range of hosts, and are divided into two subfamilies: 
Chordopoxviridae and Entomopoxviridae.  All human poxviruses are in the Chordopoxviridae 
subfamily, and most of them belong to either the Orthopoxvirus (variola, vaccinia, cowpox) or 
the Parapoxvirus (Orf virus) genus (Knipe and Howley, 2007).  Antigenically, poxviruses are 
very complex, inducing both specific and cross-reacting antibodies that have the ability to 
protect against related viruses, e.g. vaccinia virus is used to vaccinate against variola 
(smallpox).   
 
Poxviruses enters cells mainly by cell fusion through an unknown receptor, and it is thought 
that three membrane proteins, A27L, D8L, and H3L, attach to host cell glycosaminoglycans (as 
reviewed in Sauter et al., 2005).  Poxviral replication results in the formation of virus containing 
early, intermediate and late genes transcribed by viral RNA polymerase and transcription 
factors (Figure 1.2). Virus replication occurs in the cytoplasm of infected cells and after late 
gene expression produces enveloped intracellular mature virion particles (IMV) that are 
transported to Golgi to be wrapped in additional membranes becoming intracellular enveloped 
virus (IEV). IEV is transported along microtubules to reach the cell periphery and fuse with 
plasma membrane to become cell-associated enveloped virus (CEV), that triggers actin tails 
on cell surfaces or is released as extracellular enveloped virus (EEV) (as reviewed in Smith et 



















Figure 1.2 Poxvirus replication cycle Replication of poxviruses occurs in the cytoplasm of the cell and 
contains steps shown graphically in the diagram (from Keckler et al., 2005) 
 
 
Poxviruses are ideal vectors for vaccine development for several reasons.  Their large genome 
allows the insertion of multiple genes, their cytoplasm has all the tools required for replication 
without host cell integration, they are temperature stable, easily manipulated to generate 
recombinants and due to cessation of smallpox vaccination in the 1970s, there are a 
diminishing number of people with pre-existing vector immunity (as reviewed in Pantaleo et al., 
2010). 
 
Fully replication competent vaccinia virus is not safe to use as a vaccine vector, however there 
are several other poxvirus vectors that have been used in vaccine development.  These 
include the attenuated vaccinia virus strains, modified vaccinia Ankara (MVA) and NYVAC 
strain, and the attenuated canary poxvirus known as ALVAC (Belshe et al., 1998).  MVA will be 
discussed further in section 1.3.4, and ALVAC was used in the RV-144 trial (Rerks-Ngarm et 
al., 2009) as discussed in section 1.2.7.  NYVAC, based on the Copenhagen strain of vaccinia 
virus, was used in the EuroVacc 02 (EV02) phase I trial in combination with a DNA prime 

















cell responses in 90% of vaccinees (Harari et al., 2008).  Polyfunctional vaccine-induced CD4+ 
T-cell responses were seen in 100% of responders and CD8+ T-cells in 50% of responders 
(Harari et al., 2008).  T-cell responses were largely targeted to Env (91 %) with Gag, Pol or Nef 
detected in 48 % of individuals. 
 
Prime-boost vaccinations with DNA and NYVAC are safe, variably immunogenic and produce 
T-cell responses that are usually predominated by CD4+ T-cell responses directed towards 
Env (Harari et al., 2008).  This was also observed with MVA (discussed below), and appears to 
be a characteristic of poxviral vectors as a group (as reviewed in Paris et al., 2010).  Many 
factors relating to the immunogen such as dose, route, adjuvant and insert stability may 
influence the immunogenicity of the DNA/poxvirus regimen. 
 
1.3.3.4 Other vectors 
 
In light of the failure of the STEP trial, many vaccine vectors other than Ad5 are being studied.  
These include replication capable CMV, recombinant BCG and Yellow Fever Virus (Hansen et 
al., 2009; Cayabyab et al., 2009; Rosario et al., 2010; Bonaldo et al., 2010).   
 
Picker and colleagues used a replicating simian cytomegalovirus (CMV) vector expressing SIV 
Gag, Rev, Tat, Nef and Env that controlled viraemia to undetectable levels in four of twelve 
repeatedly intrarectally challenged macaques (Hansen et al., 2009).  A follow-up study of 24 
rhesus macaques receiving CMV vectors alone or CMV and an Ad5 boost showed early 
control of SIV in 13 animals and long term protection in 12 of these (Hansen et al., 2011).  
Robust long-lasting polyfunctional cellular responses, predominantly by CD8+ effector memory 
T-cells, were elicited in all vaccinated animals, although no significant binding or neutralising 
antibodies were seen.  Also encouraging was that recombinant CMV was given multiple times 
with no effect on immunogenicity (Hansen et al., 2011).  CMV causes persistent infection by 
remaining in host cells, and thus provides continuous antigen stimulation that maintains 
effector memory stimulation.  It is thought that effector memory cells offer an advantage for 
protection, as they are readily available to kill infected cells at mucosal effector sites, the sites 
of viral entry.  Central memory CD8+ T-cells, produced by current T-cell vaccine vectors such 
as MVA, although long lasting, would take longer to differentiate to effectors and be effective at 
viral entry sites.  This suggests that a vaccine based on a persistent vector is important, or that 
repeated vaccinations of a waning vaccine will be necessary (as reviewed in Franchini, 2009; 
Hansen et al., 2009; Hansen et al., 2011).  There is concern that it will not be safe to vaccinate 

















safety of CMV are currently being explored (Louis J. Picker, Keystone Symposia, Protection 
from HIV: Targeted Intervention Strategies (X8), Canada, 2011).   
 
Mycobacterium bovis BCG (rBCG) has long been used to vaccinate against tuberculosis, with 
over 3 billion doses given since the 1920s, and therefore has a proven record of safety and 
persistence (as reviewed in Joseph et al., 2004).  Thus, it is being considered as an HIV 
vaccine vector.  Recent non-human primate studies have shown that vaccinated animals 
developed only modest SIV-specific cellular responses, however responses were boosted with 
a range of other vectors, such as Ad5, MVA and yellow fever virus (Bonaldo et al., 2010).  
These boosted responses were durable, of high magnitude responses and higher than those 
generated by the other vectors alone (Cayabyab et al., 2009; Rosario et al., 2010; Bonaldo et 
al., 2010).  This suggests that rBCG may be a good prime candidate.   
 
Several other viral vectors are in development as HIV vaccine candidates, such as live 
recombinant vesicular stomatitis virus (VSV) and  Semliki Forest virus (SFV), and these have 





1.3.4.1 What is MVA? 
 
Modified Vaccinia Ankara (MVA) is a highly attenuated strain of vaccinia virus that was 
developed towards the end of the campaign for the eradication of smallpox (McCurdy et al., 
2004; as reviewed in Sutter and Staib, 2003).  MVA has lost about 10% of the vaccinia 
genome by hundreds of passages of vaccinia virus in chicken cells.  It has lost the ability to 
replicate efficiently in cells, rendering it safe for use in humans (as reviewed in Pantaleo et al., 
2010).  Like all the poxviruses, it has a large genome which allows easy gene insertion making 
ideal to act as a vaccine vector (Blanchard et al., 1998; as reviewed in Sutter and Staib, 2003).   
 
1.3.4.2 Why is MVA a desirable vector? 
 
In the 1970s MVA demonstrated its safety and efficacy in over 120 000 people vaccinated 
against smallpox (as reviewed in Paris et al., 2010).  It is even safe in immunocompromised 
persons receiving HAART (Dorrell et al., 2007).  A variety of antigens from human pathogens 

















al., 2005; Hanke et al., 2007; Sandstrom et al., 2008; Goepfert et al., 2011).  A number of 
promising experimental MVA vaccines expressing HIV, TB, malaria and tumour antigens are 
currently being evaluated in clinical trials in human volunteers (Hanke et al., 2007; Scriba et 
al., 2010).   
 
Vaccination against HIV using MVA has shown moderate success in non-human primate 
models.  Researchers have described lower and/or delayed acute viraemia and better survival 
times after challenge with SIV in vaccinated macaques compared to unvaccinated controls (Im 
et al., 2006; Horton et al., 2002).  Indeed, mucosal vaccination via the nasal route with DNA 
and MVA-based vaccines elicited stronger immune responses and longer survival in 
macaques (Ourmanov et al., 2009; Manrique et al., 2011). 
 
The most advanced HIV vaccine candidate regimen based on MVA that has been tested in 
humans is a DNA prime-MVA boost HIV vaccine candidate, tested in safety trials and in larger 
phase II studies by Oxford University and the International AIDS Vaccine Initiative (IAVI; as 
reviewed in Paris et al., 2010).  The HIVA immunogen used in the plasmid DNA and 
recombinant MVA vaccines consisted of consensus clade A Gag p24p17 sequences and 
various CD8+ T-cell epitopes.  This and subsequent studies proved that the vaccine was safe, 
but did not induce antibody responses and only moderate cellular responses (Cebere et al., 
2006; Hanke et al., 2007; Guimaraes-Walker et al., 2008).   Interestingly, all responses were 
dominated by CD4+ T-cells, with few individuals having CD8+ T-cell responses (Hanke et al., 
2007; Goonetilleke et al., 2006).  In addition, responses to the DNA and MVA combination 
were of higher magnitude and breadth than those generated by the rMVA alone (Goonetilleke 
et al., 2006).  This vaccine candidate is currently undergoing testing in larger clinical trials (IAVI 
Report 2010). 
 
Promising results have been reported by another Phase I study of a multigene, multiclade 
DNA-MVA prime boost vaccine candidate (Sandstrom et al., 2008).  A DNA and MVA 
vaccination regimen was given in combination with recombinant granulocyte macrophage 
colony-stimulating factor (GM-CSF).  Encouragingly, this vaccination regimen was safe and 
highly immunogenic with responses detected in the majority of individuals in both the CD4+ 
and CD8+ T-cell compartments (Sandstrom et al., 2008; as reviewed in Paris et al., 2010).   
Humoral responses were however poor.   Another candidate DNA-MVA vaccine regimen 
having undergone a Phase I trial produced CD4+ and CD8+ cellular responses in addition to 
antibody responses induced to trimeric Env that was includes in the vaccine construct 


















These Phase 1 trials have proven that MVA is safe, immunogenic and that priming with DNA 
generates higher T-cell responses in higher dose MVA regimens (Goonetilleke et al., 2006; 
Sandstrom et al., 2008; Goepfert et al., 2011).  It is also evident that T-cell responses are often 
dominated by CD4+ T-cells, although CD8+ T-cells responses have also been generated, and 
that the magnitude of responses are variable, according to the vaccine inserts.  The HIVA 
immunogen expressing strings of CD8 epitopes elicited much lower responses than those that 
were observed when expressing whole proteins (Hanke et al., 2007; Sandstrom et al., 2008; 
Goepfert et al., 2011).  In addition to T-cell responses, antibody responses can be generated 
by MVA vectors with envelope inserts, although it appears that higher antibody responses are 
seen in individuals having fewer or no DNA primes (Goepfert et al., 2011).  The importance of 
these antibody responses have been shown in macaque studies, where high avidity anti-Env 
binding antibody responses have been associated with control of peak viraemia following high-
dose intrarectal challenges (Zhao et al., 2009).  Thus, DNA priming induces better cellular 
immunity but lower humoral immunity.   
 
1.3.4.3 MVA-specific immune responses 
 
MVA is being considered as an alternative to Dryvax, a live vaccinia virus, as a smallpox 
vaccine in the era of bioterrorism.  MVA cannot replicate in most human cells and has fewer 
complications in high risk individuals such as the immunocompromised, very young or elderly 
individuals (Meseda et al., 2005).  MVA readily produces binding and neutralising antibodies in 
individuals vaccinated with varying doses and routes comparable to those produced by Dryvax 
(Meseda et al., 2005; Wilck et al., 2010).  Strong, predominantly CD8+ T-cell responses were 
also generated to MVA (Frey et al., 2002; Ennis et al., 2002).  These responses are long-lived 
and detectable in nonhuman primates as long as 3 years after vaccination (Nigam et al., 
2007).  Goepfert et al. (2011) recently showed that MVA-specific CD4+ and CD8+ T-cells of 
high magnitude were generated in humans.  
 
1.3.5 Anti-vector immunity 
 
1.3.5.1 What is anti-vector immunity? 
 
Anti-vector immunity refers to immune responses directed at the vector itself.  These anti-
vector immune responses can potentially dampen the immune response to the vaccine 
antigens by rapid clearance of the vaccine vector, and possibly shorter duration of antigen 
presentation to T cells as a result of cleared infection (as reviewed in Duerr et al., 2006).  It is 

















immunity may refer to pre-existing immunity to the vector, for example, with adenovirus, it is 
common that a person may have been naturally exposed to adenovirus previously.  Pre-
existing immunity to Adenovirus type 5 has been well described and may have been one of the 
contributing factors leading to the recent failure of the Merck Adenovirus HIV vaccine (McCoy 
et al., 2007; Sekaly et al., 2008).  With poxviruses such as MVA, the presence of pre-existing 
immunity to vaccinia virus in the adult population is the result of smallpox vaccination 
programs.  It is hoped that MVA will be resistant to this kind of anti-vector immunity, as routine 
vaccinia immunisation was stopped in the early 1970s, and the majority of the HIV at-risk 
population will have no pre-existing immunity.   
 
A few studies have looked at the effect of pre-existing vaccinia immunity on the generation of 
responses to vaccinia virus and MVA by vaccination.  Humoral responses and cellular 
responses following vaccination with vaccinia Lister strain were not affected by pre-existing 
vaccinia immunity, with comparable levels of both achieved in vaccinia naïve and immune 
individuals (Kim et al., 2005; Kim et al., 2006).  Similarly, MVA used as a vaccine showed no 
significant difference in the vaccinia-specific CD4+ and CD8+ T-cell responses elicited in pre-
immunised compared to vaccinia-naïve individuals (Parrino et al., 2007).  In two non-human 
primate studies of vaccinia-naïve animals, MVA cellular responses were generated by one 
vaccination, but were not significantly higher after the second MVA or subsequent vaccinations 
(Earl et al., 2004; Grandpre et al., 2009).  Dose and timing of immunisations very likely affects 
the responses.  Humoral responses generated to MVA appear to be affected by the dose, with 
higher doses generating higher binding and neutralising antibody levels, while cellular 
responses do not appear as dose dependent (Wilck et al., 2010; Keefer et al., 2011).  In other 
studies, however, it has been shown that MVA-specific cellular responses are boosted by 
subsequent vaccinations and are long-lasting (Smith et al., 2005; Nigam et al., 2007; Precopio 
et al., 2007).  MVA produces predominantly CD8+ T-cell responses and only low frequency 
and magnitude CD4+ T-cell responses (Parrino et al., 2007; Kim et al., 2006; Smith et al., 
2005; Nigam et al., 2007; Earl et al., 2004).  MVA also generates binding and neutralising 
antibody responses by two or more vaccinations that are equivalent to those generated by 
Dryvax (Earl et al., 2004; Nigam et al., 2007; Wilck et al., 2010).  Interestingly, it has been 
suggested that using MVA as an HIV vaccine vector may have a dual role in protection against 
HIV and smallpox (Nigam et al., 2007). 
 
A DNA-MVA prime boost vaccination regimen found that HIV-specific responses were elicited 
after the MVA vaccination was given in the majority of individuals (Sandstrom et al., 2008).  
However, individuals with pre-existing vaccinia-virus immunity had the same frequency of 

















vaccinia-naïve (Sandstrom et al., 2008; Gudmundsdotter et al., 2009).  They speculate that 
this was caused not only by pre-existing antibodies in these individuals, but they were also 
older and that age had a moderate negative effect on HIV responses.  In a study by Howles et 
al. (2010) this was not seen, and there was no difference in responses to HIV inserts between 
those individuals that did or did not have pre-existing vaccinia immunity, however they used a 
much lower dose of rMVA (5 x 107). A non-human primate study, where some animals 
received Dryvax 17 months prior to receiving a DNA-MVA vaccination regimen containing SIV 
inserts, showed that vaccinia-naïve animals developed SIV responses after the first MVA 
vaccination that were boosted to higher levels after the second MVA vaccination.  However, 
vaccinia-immune animals developed over twofold lower responses after the first MVA, 
responses were not boosted by the second MVA, and were twelvefold lower than in naïve 
animals (Kannanganat et al., 2010).  However, even though the magnitude of the SIV-specific 
responses was affected by pre-existing vaccinia immunity, upon challenge these animals did 
not show poorer control of virus than the vaccinia-naïve animals. 
 
Anti-vector immunity also refers to immunity generated by the vaccination regimen itself. 
Individuals may have never been exposed to the vector before, so the first vaccination may 
generate immune responses to the vaccine antigens presented, as well as the vector itself, 
and upon subsequent or boost vaccinations with the same vector, vector-specific immune 
responses generated after the first immunisation may dampen the effect of the second or third 
immunisations to the inserts.  It has been suggested that poxviral immune responses, even in 
the absence of prior smallpox vaccination, are always immunodominant over vector inserts 
(Smith et al., 2005).  Even if this is the case, it is interesting to study what happens to the insert 
specific immune responses when MVA is given more than once in individuals with no pre-
existing vaccinia immunity before vaccination.  It has indeed been observed that vector-
specific responses can negatively impact upon the immunogenicity of later vaccinations if they 
are given repeatedly (Sharpe et al., 2001).  In other non-human primate studies, SIV-specific 
CD4+ and CD8+ responses were generated to a DNA-MVA vaccine vaccination regimen, with 
CD4+ T-cell elicited at higher magnitude.  Cellular responses peaked after the first MVA 
vaccination, and were not boosted to higher levels by the second MVA vaccinations (Horton et 
al., 2002; Lai et al., 2011).  Notably though in the study by Lai et al. (2011), even though SIV-
specific cellular responses were not boosted by a second MVA vaccination, 71% of these 
animals were protected from 12 rectal challenges with SIVsmE660.  This protective effect was 
shown to correlate with the avidity of the anti-Env antibody responses. Lack of boosting of 
insert specific responses to subsequent MVA vaccines has also been described in human 
studies, where the magnitude of HIV-specific responses reached their peak after the first MVA 

















Walker et al., 2008).   Possibly combining the DNA-MVA vaccination regimen with a boost of a 
different viral vector could result in increased insert specific responses.  
 
1.3.5.2 Ad5 and STEP 
 
Adenovirus serotype 5, Ad5, is endemic around the world, with 30 – 70 % of people in the 
United States, and as many as 90 % of individuals in sub-Saharan Africa, having neutralising 
antibodies due to natural exposure (as reviewed in Sauter et al., 2005).  Anti-vector 
neutralising antibodies limit repeat administration of Ad5 vaccines, as they bind the virus and 
prevent the infection of host cells and thus delivery of vaccine antigens (Chirmule et al., 1999).   
 
The STEP trial (discussed in section 1.2.7) showed that a homologous Ad5 vaccine expressing 
HIV-1 Gag, Pol and Nef genes elicited frequent INF- responses with a limited breadth of 
response, but failed to protect against HIV (McElrath et al., 2008; Buchbinder et al., 2008).  
Indeed, vaccinated individuals with pre-existing Ad5-specific neutralising antibodies (titres > 
18) showed a 2.3-fold higher incidence of HIV-1 acquisition (Buchbinder et al., 2008; as 
reviewed in Corey et al., 2009).  It was also shown that uncircumcised men, mainly those that 
were Ad5 seropositive, had almost a four-fold higher incidence of HIV infection (as reviewed in 
Corey et al., 2009).  There was no increase in HIV acquisition seen in vaccinated Ad5 
seronegative individuals.   It is thought that the lack of efficacy may be due to the immune 
response generated by the vaccine being too narrow, where on average only one epitope in 
each of the Gag, Pol and Nef genes in the vaccine were produced in most vaccinated 
individuals (as reviewed in Corey et al., 2009).   This may be because continued boosting with 
the same vector (homologous boosting) can enhance immunodominance of the T-cell 
response (Smith et al., 2005). 
 
In addition to determining lack of protective effect of the vaccine, investigations are on-going to 
determine the cause of increased incidence of HIV acquisition among vaccinated individuals.  
The effect of circumcision and other epidemiologic confounders make it difficult to determine 
the cause, however a number of mechanisms have been suggested (as reviewed in Corey et 
al., 2009).  Notably this effect was not seen in the Phambili trial in South Africa with the same 
vaccine (Gray et al., 2011). First, it is thought that vaccination in individuals with previous 
immunity to Ad5 have activation and expansion of their Ad5-specific CD4+ T-cells resulting in 
an increase in target cells for HIV to infect (Sekaly et al., 2008).  Activation was speculated to 
be mediated by the formation of Ad5 immune complexes (Perreau et al., 2008).  Hutnick et al. 
(2009) studied Ad5-specific CD4+ T-cell responses and Ad5 neutralising antibody titres in 

















in the magnitude, phenotype, function, proliferative capacity or circulating numbers of Ad5-
specific CD4+ T-cells between Ad5 seropositive and seronegative individuals.  Ad5 responses 
may, however, need to be assessed in mucosal tissues also.  Finally, pre-existing Ad5 
immunity may have other effects, such as production of enhancing antibodies that facilitate 
HIV infection (as reviewed in Corey et al., 2009).  There are likely other causes that need to be 
identified, and it is probably a result of a combination of many factors. 
 
1.3.5.3 Attempts to reduce anti-vector immunity 
 
Heterologous prime-boost strategies involve sequential immunisation with a common antigen 
incorporated into different vectors, such as a DNA prime vaccine and viral vector boost 
vaccine. This regimen has been shown to result in larger numbers of antigen-specific CD8 T 
cells than achieved by a single vaccine administration or homologous boosting by focusing the 
boost response on the vaccine antigens expressed in the vectors and preventing anti-vector 
immunity arising as a result of repeated administration of the same viral vector (Goonetilleke et 
al., 2006; Sandstrom et al., 2008; Goepfert et al., 2011; Harro et al., 2009; Gudmundsdotter et 
al., 2009). DNA priming has been shown to overcome pre-existing vaccinia immunity in 
macaques vaccinated with an MVA-Ebola Glycoprotein vaccination (Yang et al., 2003). 
 
In addition to heterologous prime-boosts researchers are attempting to reduce pre-existing 
immunity by using different Adenoviral serotypes (section 1.3.3.2), developing alternative 
vaccine vectors (section 1.3.3.4) or modifying existing vaccine vectors (Naito et al., 2007; 
Roberts et al., 2006).  Roberts et al. (2006) engineered Ad5 to remove neutralising epitopes on 
the viral surface.  They replaced these epitopes with corresponding regions from Ad48, which 
is uncommon in humans.  The vaccine showed good immunogenicity in nonhuman primates, 
even in the presence of pre-existing Ad5-specific immunity (Roberts et al., 2006).  Modification 
of the capsid structure of recombinant MVA or deletion of antigenically complex genes has 
shown that MVA can also be engineered to be resistant to pre-existing immunity (Naito et al., 




























1.4 Aims and Objectives 
 
The HIV vaccine group at UCT has developed a candidate HIV vaccine, consisting of MVA 
expressing several genes from HIV-1 subtype C.  This vaccine is a component of an 
immunisation regimen that is currently in Phase I clinical trials, and has been given as multiple 
vaccinations to boost a recombinant DNA vaccine expressing the same HIV genes.  HIV-
specific immune responses generated by the vaccines have been evaluated in preclinical trials 
in non-human primates.  These studies reveal that the candidate vaccines generate potent 
HIV-specific immune responses that peak one week after MVA immunisation (Burgers et al., 
2009).  An interesting observation from this study was that MVA vaccinations given in close 
succession do not appear to boost responses to HIV antigens further, although these 
responses are boosted when MVA is given one year after the previous MVA vaccination.  It is 
possible that anti-MVA immunity, i.e. immunity to the vector itself, limits the magnitude of the 




The aim of this study was to determine whether anti-vector immunity to MVA inhibits the ability 
to boost immune responses to the HIV antigens expressed by the vector in successive 
immunisations, and investigate the nature of MVA-specific immunity. 
   
1.4.2 Hypothesis 
 
Immune responses to the MVA vector inhibit immunity to the HIV antigens it expresses. 
 
1.4.3 Specific Objectives 
 
1. To optimise methods for detecting immune responses generated against the MVA 
vector. 
2. To investigate humoral responses to MVA, including binding and neutralising 
antibodies. 
3. To investigate cellular responses to MVA, including their magnitude, functional nature 
and memory phenotypes. 
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There were two aims to this study.  The first was to measure humoral responses to MVA in 
preclinical immunogenicity studies in non-human primates, including both binding and 
neutralising antibody responses, and the second was to determine the magnitude, phenotype 
and function of T-cell responses to MVA in these animals.   
 




Nine wild-caught Chacma baboons (Papio ursinus) were used in a previous study describing 
the immunogenicity of candidate HIV vaccines (Burgers et al., 2009).  Archived cryopreserved 
PBMC and serum samples from eight of these animals from multiple time points were used for 
this study.  One animal (B630) was excluded from the study because of insufficient sample 
availability.  Animals were housed in the South African Medical Research Council (MRC) 
Primate Facility in Cape Town.  This study also included limited analyses (only determination 
of neutralising antibody titres) on 22 macaques from a similar study using the same vaccine 
candidates.  The macaques were housed at the same facility.  All studies were approved by 
the Animal Ethics Committee of the Faculty of Health Sciences, University of Cape Town.   
 
Chacma baboons are not widely used as the animal model of choice in vaccine research.  
However, at the time these experiments were performed, they were the only non-human 
primates available in Cape Town to perform preclinical immunogenicity studies for candidate 
HIV vaccines, prior to the subsequent establishment of a breeding colony for rhesus 
macaques.  There are numerous advantages to this model, such as the high homology 
between human and baboon immune system components (Damian et al., 1971), lack of 
sensitivity to infection with Herpes B virus (Kennedy et al., 1997) and thus a lower safety risk 
for handlers, and their larger size which allows greater blood draw volumes for use in 
immunological testing.  They are also outbred, which ensures a diverse genetic background 
between animals, similar to the situation in humans tested with vaccines (Murthy et al., 2006).  
They have also been used in various safety and immunogenicity studies of HIV vaccine 
candidates, and it has been shown that they can present HIV peptides containing epitopes 
recognised in HIV-infected humans (Burgers et al., 2009).  Immune responses have been 
generated in baboons in response to vaccination with a DNA and MVA expressing HIV 

















al., 2008), as well as a rBCG prime and Gag VLP vaccine (Chege et al., 2009).  All these 




2.2.2 Vaccines and immunisations  
 
Two vaccine constructs were given in a prime-boost regimen.  They consisted of DNA (termed 
SAAVI DNA-C) and recombinant MVA (SAAVI MVA-C), as depicted in Figure 2.1.  SAAVI 
DNA-C contained an equal mixture of two plasmids, pTHr.grttnC and pTHr.gp150CT, and 
expressed five human codon-optimised HIV-1 subtype C genes, namely Gag, RT, Tat, Nef 
(GRTTN) and a C-terminal truncated Envelope gp150CT under the early promoter enhancer 
element from human cytomegalovirus. All genes were derived from subtype C strains Du151 
and Du422, and modified to be non-functional to increase safety and immunogenicity (Burgers 
et al., 2006).  SAAVI MVA-C consisted of a live recombinant MVA that expressed the same 
five codon-optimised, non-functional HIV-1 subtype C genes (GRTTN and truncated Env 
gp150CT).  The MVA was obtained by Therion Biologics (Cambridge, MA, USA) from Dr. 
Anton Meyer, University of Munich, Germany.  It w s three times purified on primary chicken 
embryo dermal (CED) cells, amplified and used to generate a master virus stock, TBC-MVA 
MVS lot 1.  This was used to generate the recombinant MVA.  Construction of the recombinant 
MVA has been described (Burgers et al., 2008).  Briefly, Env was expressed by the weaker 
vaccinia virus promoter I3, to increase stability of the virus, and GRTTN under the control of 
the vaccinia early-late-40K promoter.  For the 22 vaccinated macaques, eight were primed with 
SAAVI DNA-C2, which differed from DNA-C in the regulatory elements, in that it contained a T-
cell leukaemia virus type 1 regulatory (HTLV1-R) element in addition to the CMV promoter 
(Barouch et al., 2005).  This was shown to enhance the immunogenicity of HIV DNA vaccines 
in mice and nonhuman primates (Barouch et al., 2005).  Since there were no differences in 
HIV-specific responses between the macaques that received DNA-C or DNA-C2, these were 


























Figure 2.1 SAAVI DNA-C and SAAVI MVA-C vaccine constructs.  The constructs contain genes 
encoding HIV-1 subtype C Gag, RT, Tat, Nef and truncated Env. SAAVI DNA-C encodes the genes 
under control of the CMV intermediate-early promoter, whereas the SAAVI DNA-C2 construct given to 
macaques (not depicted) contained the HTLV1-R enhancer.  SAAVI MVA-C expressed the same genes 
under control of the I3 and 40K promoters in a single recombinant virus. 
 
 
Five of the eight baboons (B515, B534, B531, B549 and B575) received three SAAVI DNA-C 
priming vaccinations of 4 mg one month apart, delivered intramuscularly.  The remaining three 
animals (B533, B623 and B629) received empty DNA with no insert according to the same 
regimen.  All eight animals received SAAVI MVA-C (109 pfu) 33 weeks later (week 41), and 
two months later at week 49.  One year after the second MVA boost, at week 105, four animals 
(B515, B549, B575 and B623) received a third MVA-C boost (Figure 2.2 A).  The immunisation 
regimen for the macaques was slightly different, as it was based on the proposed schedule for 
Phase I clinical trials (Figure 2.2 B).  Eight macaques (P18, P23, P24, P27, P37, P41, P45 and 
P67) received three SAAVI DNA-C priming vaccinations of 4 mg one month apart, delivered 
intramuscularly.  A further eight macaques (P3, P28, P30, P31, P32, P34, P36 and P38) 
received three SAAVI DNA-C2 primes.  The remaining six animals (P1, P2, P5, P25, P36A and 
P66) received no DNA vaccination.  All 22 macaques received SAAVI MVA-C (109 pfu) eight 

































Figure 2.2 Immunisation schedules. (A) Five baboons received three SAAVI DNA-C (4 mg) priming 
vaccinations and three received DNA with no vector.  All baboons received SAAVI MVA-C (10
9
 pfu) at 
week 41 and 49.  At week 105, four baboons received a third MVA-C boost. (B) Sixteen macaques 
received three SAAVI DNA-C (4mg) or SAAVI DNA-C2 (4mg) priming vaccinations and six received 
DNA with no vector.  All macaques received SAAVI MVA-C at week 16 and 20.  
 
 
2.2.3 Sample collection 
 
Blood samples were collected from the animals at various time points pre- and post-
immunisation.  This included 20 – 60 ml whole blood, not exceeding 6.6 ml/kg body mass per 
animal per occasion, collected by venepuncture of the femoral vein into Heparin vacutainer 
tubes (BD) and 5 – 10 ml into serum separator tubes (SST; BD).  Heparin blood samples were 
used for isolation of peripheral blood mononuclear cells (PBMC).  The SST samples were used 




A range of antigens were used in the immunological assays (Table 2.1).  Purified vaccinia virus 
membrane proteins A27, A33, B5R and L1R were obtained from Dr Gary H. Cohen and Dr 
Roselyn J. Eisenberg, School of Dental Medicine, University of Pennsylvania, for use in ELISA.  
These vaccinia proteins were produced using a baculovirus expression system and have been 
used previously for detection of MVA antibodies (Aldaz-Carrol et al., 2005; Cosma et al, 2007; 
Earl et al, 2007; Parrino et al, 2007).   A27 and L1R are intracellular mature virion (IMV) 

















among hosts, while A33 and B5R are membrane proteins involved in the formation of 
extracellular enveloped virus (EEV) which is involved in cell to cell viral spread (Smith et al., 
2002).     
 
For MVA-gfp (green fluorescent protein) neutralisation assays, recombinant MVA-gfp was 
obtained from Michael Cottingham, University of Oxford.  MVA used in T-cell assays 
(ELISPOT and intracellular cytokine staining) was obtained from Bernard Moss, National 
Institutes of Health.   MVA and MVA-gfp were grown on the chorioallantoic membranes 
(CAMs) of 9-12 day old fertilised hens' eggs (modification of method of Westwood et al., 1957) 
and the titre determined in baby hamster kidney (BHK-21) cells.  A rabbit anti-vaccinia 
antibody (Biogenesis Ltd) and swine anti-rabbit HRP (Dako) were used for immunostaining to 
determine the viral titres expressed as plaque forming units per ml (pfu/ml).  Niki Douglass and 
Anke Binder, University of Cape Town, grew up the virus and performed the titrations, 
respectively.  The titre of MVA-gfp was 2 x 108 pfu/ml and the titre of MVA was 8.5 x 108 
pfu/ml.  Aliquots of each were stored at -70°C.   MVA-gfp and MVA were used at a multiplicity 
of infection (MOI) that was optimised as described in Chapter 3.  MOI is the ratio of virus to the 
ratio of target cells (Knipe and Howley, 2007).   
  
Synthetically synthesized HIV-1 subtype C peptides overlapping by 10-11 amino acids each 
were used to simulate HIV-specific responses for detection by intracellular cytokine staining.  
The peptides were synthesized using 9-Fluorenylmethoxy carbonyl chemistry and standard 
based solid phase techniques (Masemola et al., 2004). They varied in length between 15 and 
18 amino acids, overlapping by 10-11 amino acids to ensure that when combined into pools, 
the whole gene is expressed and no epitopes are lost.  Gag consisting of 121 15-18 mer 
peptides from Du422, was obtained from the NIH Research and Reference Reagent 
Repository, USA.  Nef consisting of 50 15-18 mer peptides from Du151 was kindly supplied by 
Prof. Clive Gray of the National Institute of Communicable Diseases, South Africa.  The Du 
HIV strains were used because they are close to a South African consensus sequence 
(Williamson et al., 2003).  They were all received in lyophilised form and resuspended in 
dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a concentration of 10 mg/ml.  One aliquot of each 
peptide was further diluted in RPMI (Invitrogen) to a concentration of 40 g/ml, and stored at -
70°C.  HIV peptides were combined into a Gag and a Nef pool, and used at a final 























TABLE  2.1   Antigens used in immunological assays 
 
Reagent Description Working 
concentration 
Manufacturer 
A27 IMV (Intracellular mature virion) 
purified vaccinia membrane 
protein 
1 mg/ml University of 
Pennsylvania 
A33 EEV (Extracellular enveloped 
virus) purified vaccinia 
membrane protein 
1 mg/ml University of 
Pennsylvania 
B5R EEV purified vaccinia membrane 
protein 
1 mg/ml University of 
Pennsylvania 
L1R IMV purified vaccinia  
membrane protein 
2 mg/ml University of 
Pennsylvania 
MVA-gfp MVA expressing green 
fluorescent protein (GFP) 
reporter gene  
 MOI optimised 
(Chapter 3) 
In-house 







A pool of 121 15-18 mer Gag 
peptides overlapping by 10 
amino acids:  HIV-1 subtype C 
Du422 
2 g/ml Natural and Medical 
Sciences Institute, 




A pool of 50 15-18 mer Gag 
peptides o erlapping by 10 
amino acids:  HIV-1 subtype C 
Du151 
2 g/ml Natural and Medical 
Sciences Institute, 




2.3 Sample processing 
 
2.3.1 PBMC Isolation 
 
Cell based immunology assays require the isolation of peripheral blood mononuclear cells 
(PBMC) from freshly anticoagulated whole blood.  The method involves layering of whole 

















diatrizoate solution with a density of 1.077 g/ml.  Upon centrifugation, this solution aggregates 
the erythrocytes and granulocytes, causing them to sediment.  Mononuclear cells, consisting 
mainly of lymphocytes, do not aggregate and remain at the plasma-Ficoll interface.  
Contamination by erythrocytes is minimal, and most platelets are removed during subsequent 
washing steps (Detrick et al., 2006). 
 
Heparinised whole blood (20-60 ml) was collected from each animal by venepuncture and 
density gradient centrifugation performed within 5 h.  All processing was performed at room 
temperature.  Briefly, 15 ml Ficoll was added to 50 ml Leucosep tubes (Greiner Bio-one) and 
centrifuged at 1000 x g for 1 min to force the Ficoll below the separation filter.  Blood (not 
exceeding 30 ml) was poured into the Leucosep tubes on top of the separation disk and 
centrifuged for 15 min at 1000 x g to separate the erythrocytes, mononuclear cells and plasma 
(Figure 2.3).  Cells from the interface were removed carefully being sure not to remove too 
much supernatant containing plasma proteins and platelets, or too much of the Ficoll 
containing residual granulocytes.  The cells were washed twice in wash buffer, consisting of 
PBS containing 1% FBS, resuspended in a fixed volume of wash buffer and counted (section 
2.4.2) to determine cell number and viability.  They were then cryopreserved (section 2.4.3) 





Figure 2.3 Density gradient centrifugation for PBMC isolation using the Leucosep method. (A) 
After centrifugation, separation of blood components into plasma, mononuclear cells and erythrocytes 



















2.3.2 Cell Counting 
 
Two cell counting techniques were performed.  Manual counting of freshly isolated PBMC was 
performed by trypan blue (Sigma-Aldrich) staining to determine the optimal concentration for 
long term storage of cells.  Trypan blue is used in dye exclusion procedures for viable cell 
counts.  Non-viable cells take up the trypan blue because of damage to the cell membrane, 
and stain dark blue, while viable cells remain refractile.   An automated cell counter (Guava; 
Millipore) later became available, and automated counting of thawed PBMC was subsequently 
performed.  The ViaCount reagent (Millipore) contains two fluorescent DNA-binding dyes that 
differentially stain viable and non-viable cells based on their permeability to the dyes. 
 
Manual cell counting 
Counting was performed using a haemocytometer, as shown in Figure 2.4.  The count was 
performed by loading a 1:1 dilution of cell suspension in 0.4% trypan blue into the well of an 
Improved Neubauer counting chamber (Hausser Scientific).  The numbers of viable nucleated 
cells and nonviable cells that appeared in the top-left square (A) and bottom-right square (B) of 





Figure 2.4 Improved Neubauer counting chamber.  The grid is divided into 9 large squares, each 
1mm x 1mm, by triple lines. There are four large outer squares that consist of 16 smaller squares.  
Viable and non-viable cells in outer squares A and B were counted (image adapted from Experimental 





















The Neubauer chamber is designed so that the total number of cells in one set of 16 corner 
squares is equivalent to the number of cells per l (1000 cells per ml).  Thus, to obtain the 
concentration of viable cells, the count of viable cells from the two sets of 16 corner squares (A 
and B in Figure 2.3) was added, divided by two to average them and then multiplied by two to 
adjust for the 1:2 dilution in trypan blue.  Viability is the percentage of viable cells to total cells 
counted. 
 
Automated cell counting 
Automated cell counting was performed using the Guava ViaCount assay and Guava Personal 
Cell Analysis system (PCA; Millipore) that contains a green laser.  The ViaCount assay is 
performed using the ViaCount application that is part of the CytoSoft software, version 2.1.4.  
A 1:20 dilution of cells in Guava ViaCount reagent was incubated in 2 ml microtubes (QSP) for 
8 min at room temperature in the dark.  All stained nucleated cells were counted and FSC 
properties used to separate cell debris from actual cells and provide absolute cell counts and 
viability.  Once these counts were obtained, the appropriate cell concentration adjustments 
required for the assay were made. 
 
 
2.3.3 Cryopreservation and thawing of PBMC 
 
After PBMC were isolated and counted, they were ready for cryo-preservation and storage in 
liquid nitrogen for long periods of time before use.  This process involves freezing cells in a 
media containing DMSO, which is cryoprotectant agent that protects the cells by eliminating 
formation of ice crystals that can damage cell membranes and result in cell death (Weinberg et 
al., 2000).  In addition, the temperature of the samples is gradually lowered in cryo freezing 
containers (Mr Frosty; Nalgene) that contain isopropanol (Sigma-Aldrich) which controls the 
rate of freezing to -1°C/min and a -70°C freezer.  This protects protect the samples from 
release of energy in the form of heat when it changes in state from liquid to crystalline form.   
 
All cryo-preservation work was carried out on crushed ice to limit the damage to the cells by 
the toxicity of DMSO.  After cell counting, the PBMC were centrifuged at 320 x g for 10 min.  
They were then resuspended carefully drop-wise in fresh ice-cold freezing to a final 
concentration of 10-15 x 106 cells/ml.  Aliquots of one ml were pipetted into pre-cooled labelled 
cryovials (Greiner Bio-one) and transferred into cooled Mr Frosty containers.  The Mr Frosty 
container was kept at -70ºC overnight, and the cells transferred within 24 h to liquid nitrogen 


















PBMC were carefully and quickly thawed to protect them against damage by osmotic swelling 
upon rehydration, as well as the toxicity of DMSO.  PBMC vials were removed from liquid 
nitrogen and kept on dry ice until ready to be thawed. They were placed in a waterbath at 37C 
until the cell suspension was almost completely melted or a small bit of ice remained. Cells 
were added to a 50 ml centrifuge tube (Sterilin) and 10 ml of pre-warmed R1 (Table 2.2) was 
added drop-wise while swirling the cells.  Cells were washed by topping up to 25 ml with R1 
and centrifuging at 230 x g for 10 min to remove the DMSO.  The supernatant was decanted 
and cell pellet resuspended in 500 l of 0.02 mg/ml DNAse (Roche) for 2 min.  DNAse 
prevents clumping of the cells by digesting DNA and hydrolysing the phosphodiester linkages 
resulting in a mixture of oligo- and mononucleotides. Cells were washed as before then 
resuspended in R20 at a concentration of between 2 and 4 x 106 cells/ml without exceeding 5 
ml in a tube and left overnight at 37°C with 5% CO2. The following morning cells were 
resuspended cells gently and the cell count and viability determined.  Cells were washed in 25 
ml R10 then adjusted to 2 x 106 cells/ml for use in the IFN- ELISPOT assay. 
 
2.4 Detection of antibody responses to MVA 
 
2.4.1 Binding Antibody responses by Indirect ELISA 
 
Enzyme-Linked ImmunoSorbent Assay (ELISA) can detect the presence of antibody or antigen 
in a sample (Hornbeck et al., 2001).  In indirect ELISAs, an antigen of known concentration is 
adsorbed onto wells of a plastic plate.  After washing to remove excess antigen, the test item, 
such as serum containing an unknown amount of antibody, is incubated with antigen.  If 
present, antibody binds to adsorbed antigen and this is detected by means of a secondary 
antibody conjugated to an enzyme specific for a particular substrate.  This then results in a 
colour change that is used to quantify the relative amount of specific antibodies present. 
  
MaxiSorp flat bottom plates (96-well; Nalgene) were coated overnight at 4ºC with purified 
vaccinia virus proteins in carbonate buffer (pH 9.6; Sigma-Aldrich) at 1 mg/ml (A27, A33 and 
B5R) or 2 mg/ml (L1R).  Plates were washed six times with sterile phosphate-buffered saline 
(PBS, pH 7.4; Sigma-Aldrich) using an Autostrip Elx50 Plate Washer (BioTek), then incubated 
at room temperature for 2 h with 0.5% polyvinyl alcohol (PVA; Sigma-Aldrich) to remove any 
unbound antigen (Studentsov et al., 2002).  Frozen sera samples were thawed and diluted 

















added to the wells in duplicate.  After incubation at 37°C in 5% CO2 for 2 h, plates were 
washed as before, followed by incubation with a 1:6000 dilution of anti-monkey IgG-peroxidase 
conjugate (Sigma-Aldrich) in 0.8% polyvinylpyrrolidone (PVP; Sigma-Aldrich) at 37ºC for 1 h.  
After washing to remove unbound conjugate 100 l TMB (tetramethylbenzidine) peroxidase 
substrate (KPL) was added per well for 10 min at room temperature in the dark.  The reaction 
was stopped by adding 50 l 2N sulphuric acid (Sigma-Aldrich) to each well.   Optical densities 
were determined within 30 min at a wavelength of 450 nm by using a VersaMax microplate 
reader (Molecular Devices) and SOFTmax PRO software (Version 4.3.1).  
  
Negative and positive controls were included on each plate.  There were three negative 
controls, namely PVA only wells, wells that received no secondary antibody and wells that 
received no substrate.  These negative controls were included to ensure that there was no 
background interference by the sample diluent, secondary antibody or substrate.  Negative 
controls receiving no secondary antibody and no substrate were not to exceed the optical 
density of the PVA negative control.  The positive control consisted of reference vaccinia 
immune globulin (VIG; kindly provided by Dr Christine Anderson, Food and Drug 
Administration, USA).  All controls and samples were set up in duplicate and the optical density 
of the negative PVA control subtracted from each sample. Sera were initially screened for 
reactivity at 1:40, and positive samples subsequently titred using two-fold dilutions starting at 
1:40.  A positive response was taken as a response greater than twice the response for the 
pre-immune sera of the same animal run concurrently.  Results are expressed as end-point 
titres, which is the reciprocal of the highest dilution whose optical density value was greater 
than twofold over the pre-immunisation sera at the lowest dilution. 
 
2.4.2 Neutralising antibody responses by MVA-gfp neutralisation assay 
 
Virus neutralisation assays measure a reduction in viral infectivity as a result of neutralising 
antibodies. Traditionally this was measured by means of plaque reduction neutralisation tests 
(PRNT), which showed fewer foci of infection in mammalian cell monolayers in the presence of 
neutralising activity.  Disadvantages of PRNTs are that they are time-consuming, labour-
intensive and subject to visual user interpretation that can be a source of error (Earl et al., 
2003).  Newer assays have been developed that use MVA expressing green fluorescent 
protein reporter gene (MVA-gfp), and MVA-gfp infected cells are quantified by flow cytometry 
(Earl et al., 2003; Cosma et al., 2004).  This assay can be performed more rapidly than 
traditional PRNTs, and flow cytometric analysis excludes some of the subjectivity and user 

















performed more rapidly than traditional PRNT, and flow cytometric analysis excludes some of 
the subjectivity and user error.  Decreased fluorescence relative to the maximum percentage 
of GFP expressing cells indicates that virus has been neutralised by some degree by the sera 
being tested (Earl et al., 2003; Cosma et al 2004).  The protocol described below is based 
closely on that described in Earl et al., 2003, although they used vaccinia virus and not MVA.  
HeLa cells were chosen as the cell line to use since they are easy to culture and MVA 
undergoes a block in assembly that does not allow it to undergo replication or grow 
permissively in these cells (Sancho et al., 2002).  Thus, there is no secondary infection of cells 
with new MVA virus particles, and the MOI can be controlled. 
 
All tissue culture reagents used are summarised in Table 2.2.  HeLa cells were maintained in 
culture using D10 in 200 ml tissue culture flasks (Corning).  Cell cultures were split every two 
to three days when they reached confluency to maintain healthy, viable cell cultures at a 
density of between 2 - 5 x 105 cells/ml. 
 
TABLE  2.2 Commonly used tissue culture reagents 
 
Reagent Description Manufacturer 
RPMI-1640 Cell culture growth media containing Glutamax-I and 25 
mM HEPES 
Invitrogen  
DMEM Dulbeccos modified Eagle’s medium, containing amino 
acids and vitamins for cell culture 
Invitrogen  
PBS  Phosphate buffered saline pH 7.2 without CaCl2 or MgCl2 Invitrogen  
FBS Heat Inactivated foetal bovine serum Delta bioproducts  
Penicillin 
Streptomycin 
Antibiotic mix containing 5000 units/ml Penicillin and 5000 
units/ml Streptomycin 
Invitrogen  
Fungin Soluble form of Pimaricin, an anti-fungal agent  Invitrogen  
Trypsin A serine protease that hydrolyses proteins and is used for 
dissociation of tissues and cells 
Sigma-Aldrich 
R1 1% FBS in RPMI + 50 mg/ml Penicillin Streptomycin In-house 
R10 10% FBS in RPMI + 50 mg/ml Penicillin Streptomycin In-house 
R20 20% FBS in RPMI + 50 mg/ml Penicillin Streptomycin In-house 
D10 10% FBS in DMEM + 50 mg/ml Penicillin Streptomycin + 
0.8 mg/ml Fungin 
 
Freezing solution 10% DMSO + 90% FBS In-house 
 
Once HeLa cells reached at least 80% confluence, they were treated with 5 ml of 2.5 mg/ml 
trypsin for 2 min at 37°C to dislodge them from the culture flask.  Cells were then well 

















and that they were in suspension.  The trypsin was deactivated by adding 2 ml FBS.  Cells 
were counted manually as described in section 2.4.2 below and adjusted to a count of 5 x 106 
cells/ml in D10.  Frozen serum samples were thawed, heat inactivated for 30 min at 56°C, and 
serially diluted (starting at 1:40) in D10.  A pre-determined dilution of VIG was prepared as a 
positive control (see Chapter 3).  Each dilution was performed in duplicate.  MVA-gfp, at an 
optimised MOI (see Chapter 3), was added to 50 l of each sera dilution or control in 96-well 
round bottom tissue culture plates (Nalgene). The plate was incubated for 2 h at 37ºC.  During 
this incubation step, the plate was gently agitated by hand every 15-20 min to allow maximum 
contact between any neutralising antibodies present in the sera and the viral particles.  After 
this period, 50 l of the HeLa cell suspension was added to the wells and the plate incubated 
for 2 h at 37ºC to allow cell infection to take place.  Next, the plate was washed twice with 100 
l per well of D10 by centrifuging for 10 min at 320 x g and excess supernatant removed 
carefully with a pipette. The plates were then incubated at 37°C for a pre-determined length of 
time (see Chapter 3).  Plates were washed with 100 µl per well PBS by centrifuging for 3 min 
at 1000 x g.  Cells were removed by treatment with trypsin as before, with 50 l per well and 
10 l FBS to halt the reaction.  Cells were then fixed with 100 l CellFIX (BD) and transferred 
to FACS tubes for flow cytometric acquisition within 24 h. 
 
Negative and positive control wells were included in each assay.  The negative control 
consisted of uninfected cells where no MVA-gfp was added to ensure that there was no 
fluorescence generated.  There were two positive controls, namely an infection control where 
wells received no VIG or serum, and a neutralisation control, where wells received VIG.  All 
controls were performed in duplicate.   
 
Samples were acquired on a FACSCalibur flow cytometer (BD) using CellQuest Pro software 
(Version 5.2).  The percentage GFP expression was determined by gating cells on forward 
scatter (FSC) and side scatter (SSC), and GFP expression analysed in the FL-1 channel.   A 
minimum of 100 000 total events were captured per sample. Results are expressed as 
neutralising end-point titres which is the reciprocal for the highest dilution of sera that can 
inhibit 50% or more GFP expression. 
 
The following protocol parameters were optimised; (1) the optimal time period to infect HeLa 
cells with MVA-gfp; (2) the optimal MOI of MVA-gfp for infection; and (3) the optimal 




















2.5 Detection of Cellular T cell responses to MVA 
 
2.5.1 Interferon- ELISPOT Assay   
 
The IFN- Enzyme-linked immunosorbent spot (ELISPOT) is an ELISA-based technique that 
was developed for the detection of antibody-secreting B cells (Czerkinsky et al., 1983).  It is 
widely used for studying immune responses, particularly in vaccine trials, and is robust, easy to 
perform and quality control.  It can determine both the type of response (what cytokine) and 
the magnitude of the response (number of responding cells).  Each spot that develops 
represents a single reactive cell, thus providing information at a single-cell level (Masemola et 
al., 2004; Streeck et al., 2009).  Antibodies commonly used for detecting IFN- in human 
samples were previously shown to cross-react and detect IFN- from baboons (Chege et al., 
2005). 
 
Ninety-six well polyvinylidene difluoride plates (Millipore) were coated overnight at 4ºC with 50 
l per well of 5 g/ml anti-IFN- monoclonal capture antibody (clone 1-D1K; Mabtech).  The 
following morning, the plates were washed three times with 200 l sterile PBS and then 
incubated at room temperature for 2 h with 100 l/well of R10 to remove any unbound capture 
antibody.  Cryopreserved PBMC were thawed and adjusted to a concentration of 2 x 106 
cells/ml.  They were infected with MVA for a pre-determined length of time, and added to the 
wells at a final concentration of 100 000 cells per well, in triplicate.  MVA MOI and infection 
times were optimised and are described in Chapter 3.  After incubation at 37°C in 5% CO2 for 
20-24 h, plates were washed six times with 0.05 % PBS-Tween20 (Sigma-Aldrich, St. Louis, 
MO, USA), followed by incubation with a biotinylated anti-IFN- monoclonal antibody (2 g/ml; 
clone 7-B6-1; Mabtech) at 37ºC for 2 h. After washing, 2 g/ml of Streptavidin-horseradish 
peroxidase (BD) was added to the wells and incubated for 1 h at room temperature in the dark.  
Nova Red substrate (Vector Laboratories) was prepared by adding three drops of reagent 1, 
two drops of reagent 2 and two drops of hydrogen peroxide in 15 ml sterile distilled water.  
After mixing well, 100 l was added to each well and left at room temperature in the dark until 
spots became visible and before background began to darken (approximately 6 min).  
 
Duplicate wells containing uninfected PBMC for each sample were used as negative controls, 
as well as duplicate wells containing PBMC treated with 8 g/ml phytohaemagglutinin (PHA, 

















cells and stimulates cytokine production and hence spot formation in an ELISPOT assay.  The 
number of spots per well were counted using with an Immunospot (Cellular Technology) 
automated plate counter.  The plates are first scanned using Image Acquisition software 3B 
and the spots are then counted using Immunospot version 3.1.  Results are reported as net 
spot forming units per million PBMC (SFU/106 PBMC), where uninfected PBMC wells were 
subtracted from stimulated wells.  In addition, a response was only considered to be positive 
when values exceeded a cut-off of three times greater than the background, and greater than 
or equal to 60 net SFU/106 PBMC.  
 
2.5.2 Intracellular cytokine staining (ICS) and flow cytometry 
 
Flow Cytometry measures the size, granularity and fluorescence intensity of a stream of single 
cells as they pass through a beam of laser light (Detrick et al., 2006).  Cells are labelled with 
antibody-conjugated fluorochromes and aspirated into the sample port of a flow cytometer.  As 
they pass through the laser in single file in an isotonic fluid, light is scattered and 
fluorochromes excited.  These fluorescent chemicals emit light of a different wavelength to the 
laser light source.  The analyser has a number of detectors that measure FSC and SSC.  The 
FSC detector is in line with the light beam and the SSC detector is perpendicular to it.  FSC 
gives an indication of cell volume, whilst SSC reveals the inner complexity of the cell, such as 
granules in the cytoplasm. A FACSCalibur flow cytometer (BD) has two lasers and four 
detectors and was used for neutralisation assays described above, whereas the LSRII (BD) 
used in ICS has three lasers and 14 detectors, allowing more complex staining panels (Figure 
2.5).  The analysers both have optical coupling systems that convert the detected light signals 




Cytokines may be produced in response to antigenic stimulation and can be measured by ICS 
and flow cytometry (Chattopadhyay et al., 2008).  In addition to the antigen stimulation, other 
molecules are necessary to induce cytokine production.  This includes the co-stimulatory 
molecules anti-CD28 and anti-CD49d, which work together with presentation of the antigen to 
provide a signal to the T-cells via the T-cell receptor (TCR).  This triggers the induction of 
transcription factors and subsequent cytokine production by the activated T-cell (Waldrop et 
al., 1997).  Brefeldin-A (BFA), an antibiotic produced by the fungus Penicillium brefeldianum, 

















golgi transport of newly synthesised proteins out of the cell (Klaussner et al., 1992) which 




Figure 2.5 Configuration of the detectors of the LSRII used in these studies. (A)  Detectors for the 
blue laser (octagon), (B) detectors for the violet laser (trigon) and (C) detectors for the red laser (trigon).  
 
 
Cryopreserved PBMC were thawed and rested overnight to reduce non-specific background 
responses (Horton et al., 2007), and adjusted to a concentration of 1 x 106 cells/ml.  Some of 
each cell suspension was removed and left unstimulated to act as a negative control, while the 
remainder was stimulated with MVA or with HIV peptide mixes (described in section 2.2.3).   
All reagents used are described in Table 2.3.  Peptide stimulations were performed in v-bottom 
tissue culture plates (Nalgene, Rochester, NY, USA) by resuspending cell pellets in 100 l a 
stimulation mix consisting of R10, 0.02 g/ml DNAse, 1 g/ml of both anti-CD49d and anti-
CD28, 0.5 g/ml BFA and 2 g/ml Gag or Nef HIV peptides.  Gag or Nef peptides were used 
based on the immunodominant peptide pool response as measured by IFN- ELISPOT and 

















before washing and staining.  MVA stimulations were performed in 15 ml tubes by incubating 1 
x 106 cells/ml with MVA at 37°C.  The cells were washed in R10 to remove excess virus, 
transferred to v-bottom 96-well plates, and incubated for a pre-determined period (Chapter 3), 
after which 1 g/ml BFA was added.  The plate was incubated a further 16 h before staining. 
 
TABLE 2.3 Common reagents used in stimulation and staining 
 
Reagent Composition Usage Supplier 
anti-CD28 Co-stimulatory molecule that 
promotes T-cell receptor 
(TCR) signalling 
1 g/ml BD  
anti-CD49d Co-stimulatory molecule that 
promotes TCR signalling 
1 g/ml BD  
DNAse I Enzyme that prevents cells 
from clumping 
0.002% Roche 
Brefeldin-A (BFA) Inhibits Golgi transport of 
newly synthesised proteins 
which allows newly 
produced cytokines to 
accumulate in the cell 
0.5 g/ml Sigma-Aldrich  
FACS wash buffer 1% FBS, 0.001% sodium 
azide (Sigma-Aldrich).  
Sodium azide prevents 
bacterial growth 
All washes and antibody 
master mixes, excluding 
washes after permeabilisation 
Prepared in lab 
Cytofix/Cytoperm 
(1x) 
Formaldehyde and saponin.  
Saponin is a detergent that 
prevents reversal of 
permeabilisation 
Permeabilisation of cells prior 
to intracellular cytokine 
staining step 
BD  
Perm Wash (1x) FBS, sodium azide and 
saponin 
Washes after permeabilisation  BD 
CellFIX (1x) 1 % w/v formaldehyde and 
sodium azide 
Final re-suspension. 
Immobilises bound antibodies 






The phenotype and functional nature of T cell responses to MVA and HIV stimulations were 
determined by staining with the antibody panels depicted in Table 2.4.  The staining panels 

















phenotype panel included three cytokines (IFN-, IL-2 and TNF-α) on one channel, PE, since 
for the purpose of phenotyping it was only necessary to detect antigen-specific cells, and not 
each individual cytokine, which was determined by the functional panel performed in parallel.  
It was also important to include a viability stain since this study used cryopreserved PBMC 
samples, which often contain a percentage of dead or dying cells due to the cryopreservation 
and thawing processes.  A violet viability stain (‘Vivid’) was used, and it enters dead or dying 
cells through damaged cell membranes, reacts with amine groups in the cytoplasm and 
enhances fluorescence, whereas it cannot enter viable cells.  Dead cells that can non-
specifically bind antibodies and increase background responses were thus excluded (Horton et 
al., 2007; Perfetto et al., 2006).  All the antibodies used have been tested and published to be 
cross-reactive with baboons (Casimiro et al., 2003; Locher et al., 2003; Chege et al., 2008; 
Burgers et al., 2009).  The procedure involves first staining for antibodies expressed on the 
surface of the cell, followed by permeabilisation of cells before staining for intracellular 
markers, such as cytokines.  The permeabilisation reagent contains saponin which creates 
holes in the cells and allows antibodies to enter.  Washes were performed with a buffer also 
containing saponin, which prevented the reversal of permeabilisation.  Before acquisition on 
the flow cytometer, cells were fixed to preserve the staining. 
 













Blue 488nm   SSC   
Blue 488nm 780/60 735LP CY7PE  TNF-α 
Blue 488nm 695/40 685LP PerCPCy5.5 CD4 CD8 
Blue 488nm 575/26 550LP PE 
TNF-α, IFN-,  
IL-2  
 
Blue 488nm 530/30 505LP FITC  CD28 CD3  
Violet 407nm 655/8 630LP Qdot-655  CD4 
Violet 407nm 440/40  Pacific Blue Vivid Vivid 
Violet 407nm 605/12 505LP Qdot-605 CD8             
Red 633nm 780/60 735LP CY7APC  CD3   
Red 633nm 720/40 690LP Alexa700  IFN- 
Red 633nm 660/020  APC CD95  IL-2  


















Throughout the staining procedure, wash steps were performed in plates by centrifuging at 
1000 x g for 3 min at 4ºC, while incubation steps were carried out for 20 min at room 
temperature in the dark.  The details of the reagents and antibodies used are listed in Tables 
2.3 and 2.5.  Cells were washed twice with PBS, then resuspended and incubated in 50 l 
PBS containing a pre-titrated volume of Vivid.  Samples were then washed twice, with 150 l 
FACS wash buffer for the first wash and 200 l FACS wash buffer for the second wash.  Cell 
pellets were incubated in 50 µl of a surface staining master mix, consisting of CD4-PerCP-
Cy5.5, CD8-QDot-605, CD95-APC, CD28-FITC and FACS wash buffer for the phenotype 
panel, or CD4-QDot-655, CD8-PerCP-Cy5.5 and FACS wash buffer for the functional panel.  
The cell pellets were washed twice and incubated with 100 l Cytofix/Cytoperm.  Two washes 
using Perm/Wash buffer were performed before incubating the cell pellets in 50 l of an 
intracellular cytokine staining master mix, consisting of CD3-APC-Cy7, IFN--PE, TNF-α-PE, 
IL-2-PE and FACS wash buffer for the phenotype panel or CD3-FITC, IFN--Ax700, TNF-α-PE-
Cy7 and IL-2-APC for the functional panel.  After two washes with Perm/Wash buffer they were 
resuspended in 150 l 1X CellFIX and transferred to FACS tubes for acquisition within  24 h on 
an LSRII flow cytometer using FACSDiva software version 6.0 (BD).  Between 300 000 and 1 
000 000 events were collected per sample.   
 
TABLE 2.5 Antibodies used in the study 
 





CD4 Peridininchlorophyll Cy5.5 (PerCP-Cy5.5) L200 0.5 BD  
CD8 Quantum Dot nanocrystal 605 (QDot-605) (7Pt-3F9) 0.25 NIH NHPRR 
CD95 Allophycocyanin (APC) DX2 1 BD  
CD28 Fluorescein isothyocyanate (FITC) CD28.2 5 BD  
CD3 Allophycocyanin Cy7 (APC-Cy7) SP34-2 5 BD 
IFN- Phycoerythrin (PE) 4S.B3 5 BD 
TNF-α Phycoerythrin (PE) MAb11 5 BD 
IL-2 Phycoerythrin (PE) MQ1-17H12 2.5 BD 
CD4 Quantum Dot nanocrystal 655 (QDot-655) (19Thy5D7) 0.5 NIH NHPRR 
CD8 Peridininchlorophyll Cy5.5 (PerCP-Cy5.5) SK-1 0.25 BD 
CD3 Fluorescein isothyocyanate (FITC) HIT3a 5 BD 
IFN- Alexa Fluor 700 (Ax-700) B27 1 BD 
TNF-α Phycoerythrin Cy7 (PE-Cy7) MAb11 5 BD 
IL-2 Allophycocyanin (APC) MQ1-17H12 1 BD 
* Titrated volume used per reaction     
#


















Gating strategy and data analysis 
The gating strategy was as follows; singlets, lymphocytes, live CD3+, followed by CD4+ and 
CD8+.  For determining the memory phenotype of antigen-specific cells, CD4+ and CD8+ cells 
were then gated to determine the total amount of cytokine produced (IL-2 or TNF-α or IFN-)  
and the expression of CD28 and CD95 within these cytokine-producing cells was determined. 
To differentiate memory subsets, CD28+CD95+ cells represented central memory cells and 
CD28-CD95+ represented effector memory cells (Sun et al., 2005).  Naïve cells (CD28+ 
CD95-) were excluded.  For functional characterisation, CD4+ and CD8+ were gated to 
determine IL-2, TNF-α and IFN- produced, and boolean combinations thereof.  All results are 
reported as net responses once the background value (unstimulated tube) was subtracted. 
 
Compensation 
Spectral overlap, where fluorescence from a single fluorochrome may be detected by more 
than one detector, can occur (Roederer et al., 2004).  To overcome this, compensation was 
performed.  This involved staining a single tube of anti-mouse or anti-rat Igκ CompBeads (BD), 
depending on the antibody origin, per fluorochrome used in the panels.  Polymer amine beads 
(Bangs Laboratories, Fishers, IN, USA) were used for compensation of Vivid, and a tube of 
negative CompBeads (BD) was included.  Briefly, 100µl of Perm Wash (BD) was added to 
CompBeads (BD), with one tube per fluorochrome.  Corresponding volumes of antibodies as 
used in the staining panels were added to the beads, incubated at room temperature for 15 
min, washed and acquired.   
 
Each compensation tube was acquired on the LSRII at the same voltages and settings as test 
samples, making sure that they were as bright as or brighter than the same fluorochrome on 
the cells being studied.  During analysis in FlowJo (Tree Star), colour compensation for each 
panel was performed automatically by subtraction of fluorescence spill-over using the 
compensation wizard.  This resulted in a compensation matrix that was applied to all samples 
so that spectral overlap between the fluorochromes was minimised. 
 
 
2.6 Statistical and data analyses 
 
All statistical analyses were performed using GraphPad Prism version 5.0.  Median values, 
interquartile ranges and ranges are presented.  For non-parametric data (such as differences 
between groups), non-paired medians were compared using the nonparametric Mann-Whitney 

















determined using the Spearman rank correlation test.  P-values of less than 0.05 were 
considered significant.  
 
Analysis of flow cytometry data was performed using FlowJo version 8.8.1 (Tree Star), 
GraphPad Prism version 5 (GraphPad Software), Pestle version 1.6.2 and Spice version 5.1 

























Optimisation of techniques to determine 
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Several of the methods described in Chapter 2 required optimisation, in order to ensure 
accurate results with study samples, lab environment and MVA constructs used in this study. 
 
3.2 Optimisation of MVA-gfp neutralisation assay 
 
Optimisation had to be carried out to optimise three steps of the assay, described in Chapter 2, 
section 2.2.2.  First, it was necessary to determine the optimal time period to infect HeLa cells 
with MVA-gfp to detect efficient expression of GFP by flow cytometry.  Second, it was 
important to determine the optimal MOI of MVA-gfp for infection, and finally, the concentration 
of Vaccinia Immune Globulin (VIG), used as a positive neutralisation control, needed to be 
determined. 
 
3.2.1 Time-course to determine the optimal infection time for MVA-gfp 
 
A time course experiment was performed using three different MOI of MVA-gfp to determine 
the length of culture time that was required for detection of MVA infection of HeLa cells, as 
measured by expression of GFP by flow cytometry.  This infection time refers to the length of 
the culture period of HeLa cells with an appropriate MOI of MVA-gfp after the initial 2 h 
infection period, following the washing step to remove excess free virus particles, and prior to 
harvesting the cells for flow cytometric detection of GFP expression.   Infection times of 1 h, 2 
h, 3 h, 4 h, 5 h and 17 h were tested at MOI of 5, 0.1 and 0.05.  Figure 3.1A shows the gating 
strategy used to determine the proportion of cells infected by MVA and expressing GFP.  HeLa 
cells were first gated on side scatter and forward scatter, and then the amount of GFP 
expression was detected in FL-1, the channel where GFP fluoresces.  There was an increase 
in GFP expression over time, from barely detectable background expression after 1 h of 
culture, to 47.4% expression after 17 h.  Figure 3.1B shows the amount of GFP expression at 
three different MOI for culture periods from 1 h to 17 h.  After a 1 h culture for all MOI, no viral 
infection was detectable, as was evident from the lack of GFP expression.  At an MOI of 5, 
expression of GFP was detected as early as 2 h (17.8%), and increased slightly every hour, 
until it reached 58.6% at 5 h.  Although GFP expression levels from the lower MOI of 0.1 and 
0.05 followed the same upward trend as the higher MOI, GFP expression levels at 5 h were 
markedly lower at these lower virus concentrations.  The greatest increase was seen after 17 h 

















stocks of MVA-gfp were limited and a 17 h culture time post infection yielded sufficient 
detectable GFP expression from a lower MOI, and this was also a practical time period from a 



































































Figure 3.1 Optimal incubation period for MVA-gfp expression in HeLa cells.  (A) Flow plot showing 
HeLa cell infection with MVA-gfp and time-course at an MOI of 0.05.  (B) GFP expression at an MOI of 5 





























3.2.2 Determining the optimal MOI for MVA-gfp  
 
Once the optimal incubation time post infection had been established, the next step was to 
determine the optimal MOI.  Eight MOI ranging from 0.005 to 0.5 were prepared by serial 
dilution to yield measurable GFP expression by flow cytometry.  An uninfected control was also 
included.  Figure 3.2A shows representative flow cytometry plots of GFP-positive cells at the 
different MOI, with the same data represented graphically in Figure 3.2B.  This experiment was 
performed in duplicate, and results were highly reproducible at each MOI tested.  In the 
uninfected control, no background expression of GFP was evident.  GFP expression was 
initially low at an MOI of 0.005 (3.53%), and increased with each increase in MOI.  At an MOI 
of 0.5, GFP expression reached 82.8%.  GFP expression of between 20% and 30% was 
considered ideal because it was readily detectable, but not too high that neutralisation of 
infection was hindered.  Thus, an MOI of between 0.025 (15.1% GFP expression) and 0.05 
(29% GFP expression) was optimal, and an MOI of 0.04 was chosen for further experiments. 
 
3.2.3 Determining the optimal amount of VIG to use as a positive assay control 
 
To maintain good quality control of assays performed, it was necessary to introduce a positive 
neutralisation control for MVA.  Reference Vaccinia Immune Globulin (VIG) was obtained from 
Dr Christine Anderson (FDA, USA), and was titrated in order to establish the optimal 
concentration to be used as a positive control.   A series of dilutions of VIG ranging from 1:5 to 
1:320 were performed.  Each dilution was incubated with MVA-gfp at an MOI of 0.04 for 2 h at 
37⁰C, agitating gently every 15 min, prior to adding the HeLa cells at 0.5 x 106 per well and 
incubating overnight.  Neutralisation (%) was calculated as the ratio of GFP expression of each 
VIG dilution to the GFP expression of the control where no VIG was added. The results are 
shown in Figure 3.3. GFP expression increased at higher VIG dilutions, as neutralisation of 
MVA decreased.  This relationship was reciprocal, as the more dilute the VIG the less capable 
it was of neutralising MVA infection, and therefore GFP expression. A VIG dilution of 1:20 
(represented by the dashed line in Figure 3.3) was considered optimal for use as a positive 
control as it neutralised almost close to 100% of infection, yielding GFP expression of 1 - 3%.  
This dilution was included in every assay performed.  In summary, the MVA-gfp neutralisation 
assay was carried out as illustrated by Figure 3.4, including a 17 h incubation time post the 
initial 2 h infection, at an MOI of 0.04, using a VIG dilution of 1:20 as a positive control.  This 
optimised technique was then used to analyse 8 baboons and 22 macaques at various time-
points to determine the magnitude and kinetics of neutralising antibody responses to MVA 












































Figure 3.2 Titration of MVA-gfp to determine optimal MOI for MVA-gfp expression in HeLa cells 
(A) Representative flow plots for MOI ranging from 0 to 0.5.  (B) GFP expression (%) at different MOI.  
Values are an average of two assays, and error bars are shown. 
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Figure 3.3 Titration of VIG to demonstrate neutralisation activity. The percentage of GFP 




3.3 Optimisation of IFN- ELISPOT assay for detection of cellular 
responses to MVA 
 
The basic IFN- ELISPOT technique performed was based on that described by Masemola et 
al. (2004).  This assay was designed to analyse cellular responses to HIV   However, for this 
study, it was adapted and optimised to detect responses to whole MVA wild type viral particles.   
 
In previous studies using MVA as a stimulus in the ELISPOT assay, three major differences in 
techniques used to infect cells with MVA were noted.  Firstly, the technique for infecting the 
cells with MVA was carried out either by mixing virus and cells directly in the wells of an 
ELISPOT plate (Smith et al., 2005), or by mixing the cells and virus in tubes, washing off the 
excess virus, and then adding the infected cells to the wells of an ELISPOT plate for incubation 
(Speller and Warren, 2002; Kim et al., 2007).  Secondly, the MOI of MVA ranged from 0.1 
(Hammarlund et al., 2003) to 10 (Speller and Warren, 2002).   Finally, the length of time that 
the cells were infected with MVA prior to incubation in the ELISPOT plate ranged from 1 h 
(Speller and Warren, 2002) to overnight (Cosma et al., 2007, Earl et al., 2007).  Therefore, 
optimisation was required to establish which infection technique, which MOI and which 
infection time would work optimally in our hands. 




























































Figure 3.4 Schematic of MVA-gfp neutralisation assay technique. Coloured blocks represent serum 
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3.3.1 Determination of optimal infection technique 
 
The first investigation performed was to determine whether cells could be infected directly with 
MVA in the well of ELISPOT plate, or whether it was necessary to pre-infect cells with MVA in 
tubes, wash off excess virus, and then transfer the infected cells into the wells of an ELISPOT 
plate for incubation and subsequent detection of responses.  Three animals (B623, B629 and 
B549), each at a different time-point following MVA vaccination, were used to investigate the 
infection technique.  The B623 sample was from a time point one week following the first MVA 
vaccination, B629 one week following the second MVA vaccination, and B549 one week 
following the third MVA vaccination.  By assaying different time-points, the chances of 
detecting a range of MVA-specific responses were maximised.  Figure 3.5A shows duplicate 
wells of an IFN- ELISPOT assay performed to compare direct infection to pre-infection, at an 
MOI of 0.1 in the same animal.  Responses to MVA were detected in all three animals.  A 
sample from a time-point prior to MVA vaccination was also included in the assay, and no 
spots were present (data not shown). Figure 3.5B shows that although responses to MVA 
differed considerably between animals, most likely due to different time-points studied, it was 
clear that the pre-infection technique was consistently superior to direct infection in all three 
animals, with a 36% to 86% (median 58%) increase in net SFU/106 PBMC.  Therefore, T-cell 














































Figure 3.5 Determination of optimal infection technique. (A) IFN- ELISPOT assay for comparison 
of direct infection (left panel) and pre-infection (right panel). (B) Net SFU/10
6
 PBMCs for direct infection 

















3.3.2 Determination of optimal MOI 
 
The same three animals were used to determine the optimal MOI to pre-infect the cells. Figure 
3.6A shows IFN- ELISPOT assays performed in duplicate at MOI of 10, 5, 1 and 0.1 in the 
same animal.  Responses to MVA were detected in all three animals at all MOI used, although 
they were very low in B629 at an MOI of 10.  Samples from a time-point prior to MVA 
vaccination were also assayed in each animal and no spots were detected (data not shown).  
Figure 3.6B shows that although responses to MVA differed considerably between animals 
and MOI, it was clear that an MOI of 0.1 resulted in greater responses in two of the three 
animals, with a two- to threefold increase in detectable responses between an MOI of 1 and 
0.1.  The third animal, B549, showed similar results at MOI of 1 and 0.1 with net SFU/106 
PBMCs of 3575 at an MOI of 1, compared to 3585 at an MOI of 0.1, but this is most likely due 
to the limit of detection being reached at greater spot numbers.  Thus, interestingly, lower MOI 
were better at detecting responses to MVA than higher MOI.  This may be due to higher MOI 
causing an increase in the number of dead and apoptotic cells (higher cytopathic effect) or 
impairment of antigen presentation capacity (Norder et al., 2010).  Therefore, T-cell responses 
were readily detectable to MVA and an MOI of 0.1 was selected for subsequent assays. 
 
3.3.3 Determination of optimal length of infection time  
 
Pre-infection with an MOI of 0.1 was selected for the assay however the optimal infection time 
required to measure MVA responses needed to be determined.  Two of the animals used 
previously (B623 and B629, both at one week after the second MVA vaccination) were initially 
tested over an infection time period of 30 min, 90 min, 3 h, 6 h, 12 h and 16 h.  As shown in 
Figure 3.7A, B623 and B629 both revealed no advantage in infection times of longer than 6 h, 
with 12 h and 16 h infection times resulting in a two- to threefold reduction in response in B623 
and no difference in B629.   Thus, it was determined that there was no benefit in infection for 
12 h and 16 h, and a further four animals were tested at various time-points after the second 
and third MVA vaccinations for an infection period of 90 min, 3 h and 6 h only.  An infection 
time of 3 h showed the highest response for five of six animals tested.  There was a trend 
towards a 3 h incubation period resulting in the greatest responses (Figure 3.7B).  Thus, a 3 h 
infection period was chosen as the optimal infection time. 
 
In summary, the IFN- ELISPOT assay to detect MVA-specific T cell responses was carried 
out as described in 2.4.5, using the pre-infection technique at an MOI of 0.1 for 3 h, before 



















Figure 3.6 Determination of optimal MOI to infect cells with MVA to detect responses in the 
ELISPOT assay. (A) IFN- ELISPOT assay for comparison of direct infection at four different MOI, of 
10, 5, 1 and 0.1.  (B) Net SFU/10
6
 PBMCs for direct infection at MOI of 0.1 (red), 1 (dark blue), 5 
(medium blue) and 10 (light blue).  
 
 
3.4 Optimisation of stimulation of T-cells with MVA in the ICS assay 
 
In order to determine the length of time that led to the optimal expression of T-cell cytokines 
after the addition of BFA, an experiment was performed in one animal (B549) at one week 
after the second MVA vaccination, using three different MOI at three different infection times.  
MVA infections were performed by mixing cells with MVA at an MOI of 0.1, 1.0 and 2.0, and 
incubating for 3 h at 37°C in 5% CO2.  Cells were centrifuged and washed in R10 to remove 
any excess virus, transferred to wells of a 96-well tissue culture plate, and then harvested 
immediately or incubated for a further 3 h or 5h (total time of 3 h, 6 h or 8 h), after which 1 

















CD3-FITC and IFN--PE, to determine cytokine production by T-cell lymphocytes. Figure 3.8A 
shows the gating strategy used to determine the levels of IFN- produced by CD3+ 
lymphocytes in response to MVA stimulation. The gating strategy was as follows: lymphocytes 
identified by SSC against FSC, CD3+ lymphocytes and finally IFN-+ cytokine production.   A 3 
h incubation before the addition of BFA induced an IFN- response of 0.1%, while a total of 6 h 
or 8 h incubation induced a twelve-fold higher net IFN- response, of 1.2% (Figure 3.8B).   
There was little difference in the level of IFN- detected between 6 h and 8 h incubation before 
the addition of BFA, yielding 1.2% vs. 1.3% IFN- expression. There was no benefit in longer 
incubation periods, as 16 h incubation showed a marked reduction in IFN- production 
(0.25%). 
 

























































Figure 3.7 Determination of optimal infection time. (A) Net SFU/10
6
 PBMCs for different infection 
times in six animals. (B) Infection times of 3 h versus 6 h, and 3 h versus 90 min, with medians and 






















Figure 3.8 Optimisation of ICS assay for detecting MVA responses.  (A) Representative flow plots 
of IFN- expression from MVA-stimulated or unstimulated T cells.  (B) Net IFN- responses by ICS for 
different incubation periods with BFA, after infection with MVA at an MOI of 0.1.  (C) Net IFN- 
responses by ICS after infection with three MOI after 6 h of BFA incubation. 
 
 
According to Speller and Warren (2002), exposure to vaccinia virus requires a chain of 
intracellular steps to facilitate antigenic presentation prior to the addition of a golgi transport 
inhibitor such as BFA.  Their study revealed that infection of between 5 h and 7 h was optimal 
to detect cytokines, whereas 3 h was insufficient and 16 h was too long, as cytokine had likely 
already been secreted.  My results support this, and 6 h incubation at an MOI of 0.1 was 
considered optimal and used in all further experiments.   
 
These methods were applied to measure neutralising antibody and T-cell responses to MVA 
generated by vaccination in non-human primates that had been vaccinated with candidate HIV 
























Investigation of humoral and T-cell responses to 




















4.1 Introduction ............................................................................................................... 57 
4.2 Humoral Responses to MVA .................................................................................... 57 
4.2.1 MVA elicits low titre binding antibody responses ......................................................... 57 
4.2.2 Neutralising antibody responses to MVA ..................................................................... 58 
4.3 Cellular responses to MVA ....................................................................................... 60 
4.3.1 MVA elicits high magnitude IFN- ELISPOT responses ............................................... 62 
4.3.2 The function and phenotype of MVA-specific T cell responses .................................... 64 
4.4 The influence of MVA-specific cellular and humoral immunity on cellular 
responses to HIV antigens ....................................................................................... 67 
4.4.1 Cellular responses to HIV in response to DNA-MVA vaccination ................................. 67 
4.4.2 The effect of vaccinia virus A33 and B5R binding antibody responses on HIV-specific 
responses ............................................................................................................................... 70 
4.4.3 The relationship between neutralising antibody responses to MVA and HIV-specific 
responses ............................................................................................................................... 72 
4.4.4 MVA-specific cellular responses do not affect HIV cellular responses ......................... 75 
4.4.5 Functional responses to MVA are dominated by single cytokine-producing cells, 
whereas responses to HIV show greater heterogeneity .......................................................... 76 
4.4.6 Phenotypic responses to MVA are identical to those of HIV ........................................ 81 
























The aim of this study was to investigate immune responses to the MVA vector of an HIV 
candidate vaccine, SAAVI MVA-C, expressing five genes from HIV-1 subtype C, namely Gag, 
RT, Tat, Nef and Env.  The need to improve our understanding of vector-specific immunity of 
HIV vaccine candidates was highlighted recently by the STEP trial, where pre-existing Ad5 
immunity was implicated in increased HIV-1 acquisition after vaccination (Buchbinder et al. 
2008).  Cellular and humoral responses to MVA were investigated in non-human primates 
vaccinated at multiple time-points pre- and post-MVA vaccination, and the effect of the vector-
specific immunity on immune responses to the HIV immunogens was determined.  Binding 
antibody responses to vaccinia virus capsid proteins A27, A33, B5R and L1R were assessed 
by ELISA, and MVA-specific neutralising antibody responses were quantified using a MVA-gfp 
neutralisation assay.  T cell responses to MVA were assessed using an IFN- ELISPOT assay, 
and further characterised by intracellular cytokine staining and flow cytometry, to measure a 
range of cytokine responses and memory phenotypes of vector-specific T cells.  Data on HIV-
specific responses shown in Section 4.4.1 - 4.4.4 were provided by Dr Wendy Burgers and 
have been published previously (Burgers et al., 2009). 
 
4.2 Humoral Responses to MVA 
 
Binding antibody responses to vaccinia virus membrane proteins A27, A33, B5R and L1R were 
assessed in eight baboons by ELISA.  In addition, neutralising antibody responses were 
analysed in the same eight baboons and in 22 macaques using an MVA-gfp flow cytometry-
based neutralisation assay.   
 
4.2.1 MVA elicits low titre binding antibody responses 
 
Sera from eight baboons were tested for the presence of antibodies to vaccinia virus capsid 
proteins A27, A33, B5R and L1R at multiple time-points pre- and post-MVA vaccination.  No 
antibody responses were detected to A27 and L1R proteins. End-point antibody titres were 
determined for sera positive for A33 and B5R proteins.  
  
No responses to vaccinia virus capsid proteins were detectable prior to MVA vaccination.  
Antibodies were first detectable in a proportion of animals 8 weeks after the first MVA 
vaccination. One week later, after the second MVA vaccination, binding antibody responses to 

















responses to A33 reached the highest titres after the second SAAVI MVA-C vaccination, 
ranging from 160 to 5120 (median 480; Figure 4.1A).  These responses subsequently waned 
but by 12 weeks after the second MVA-C vaccination (week 61) were still detectable at low 
levels in all but one animal (B575).  Two of the four animals that received a third MVA 
vaccination (B515 and B549) still had low, but detectable levels of antibodies on the day of the 
third MVA vaccination (week 104), which was 10 months after the second MVA.  All animals 
showed boosting of their responses 1 week after the third MVA vaccination, to levels very 
similar, but not higher than those after the second MVA, with a median titre of 320.  Antibody 
responses to B5R showed similar kinetics as the A33 responses, but were of lower magnitude, 
at a median of 160, 1 week after the second MVA vaccination (Figure 4.1B). End-point titres to 
B5R in a single animal (B623) were boosted to a higher level after the third MVA-C 
vaccination.  A33 titres were significantly higher than B5R responses 8 weeks after the first 
MVA vaccination, and 1 week after the second MVA vaccination (p=0.012 and 0.043, 
respectively; Figure 4.1C), and although still a trend towards higher A33 responses 1 week 
after the third MVA vaccinations, this was not significant.  There were no differences in anti-
MVA antibody responses in those animals that had received priming immunisations with DNA 
prior to MVA vaccinations (data not shown). 
 
4.2.2 Neutralising antibody responses to MVA  
 
Having established that binding antibodies to MVA were elicited by vaccination, neutralising 
antibody responses to MVA were assessed in the same eight baboons, in order to determine 
whether levels of these antibodies had any impact on the ability of the MVA and HIV-specific 
cellular responses to be boosted.  Twenty-two macaques that were undergoing pre-clinical 
testing of the same vaccines in a similar vaccination regimen were included in this analysis.  
Based on available sample numbers and due to limited serum availability, one baboon (B623) 
was selected to perform neutralisation assays at multiple time-points to ascertain which time-
point would be best suited to detect neutralising antibody responses to MVA.  This assay was 
also performed on one macaque sample to confirm the assay sensitivity and the peak time-
point, as this may have differed in the two species.   
 
No neutralising antibodies were detected prior to the first MVA vaccination at 41 weeks, or 
indeed prior to the second MVA vaccination at 49 weeks, in animal B623 (Figure 4.2A).  One 
week after the second MVA vaccination was given, neutralising antibodies were detected at a 
titre of 320.  This response subsequently waned, and by 12 weeks after the second MVA 
























































































































































Figure 4.1 Binding antibody responses to MVA.  Eight baboons were immunised with SAAVI MVA-C.  
Five of the animals had previously received three vaccinations with DNA-C (B515, B524, B531, B549, 
B575).  ELISA responses are expressed as end-point titres.  The DNA-C prime vaccinations are 
represented by grey arrows and the MVA-C vaccinations by black arrows.  Four animals (B515, B549, 
B575, and B623) received a third MVA-C vaccination. (A) Kinetics of responses to vaccinia virus 
envelope protein A33.  (B) Kinetics of responses to vaccinia virus envelope protein B5R.  (C) Magnitude 
of peak binding antibody responses to vaccinia virus envelope proteins A33 and B5R 8 weeks after one, 
and 1 week after two or three MVA-C vaccinations.  Filled symbols represent DNA-MVA vaccinated 
animals and open symbols indicate animals that received MVA only. Box and whisker plots show 
medians and ranges. Significant differences as determined by a Mann Whitney test are shown by an 

















On the day of the third MVA vaccination at week 105, no neutralising antibodies were 
detected, however the response rapidly reappeared to a titre greater than that induced by the 
second MVA vaccination, of 960.  The single macaque sample tested longitudinally (P3) 
exhibited an identical pattern, peaking at 1 week after the second MVA vaccination (no third 
MVA vaccination was given in these animals; data not shown).  Thus, sera from all eight 
baboons and 22 macaques were tested at one time-point pre-immunisation, on the day of the 
second MVA vaccination, and 1 week after the second MVA.  No baboons had any detectable 
neutralising antibodies prior to the second MVA vaccination, whereas all animals subsequently 
developed neutralising antibodies 1 week later, with end-point titres ranging from 40 to 640, 
with a median of 80 (Figure 4.2B).  Macaque neutralisation titres ranged from 40 to 640, with a 
median of 320. Neutralising antibody responses in the 22 macaques tested were significantly 
higher than the levels found in the baboons (p=0.04; Figure 4.2C).  There were no differences 
in neutralising antibody responses in those animals that had received priming immunisations 
with DNA prior to MVA vaccinations (data not shown).  The relationship between B5R and A33 
antibody responses and neutralising titres were examined in baboons, to investigate whether 
responses to these capsid proteins were related to MVA neutralising activity.  There was no 
relationship between B5R responses and neutralising antibodies at matching time-points 
(p=0.46, r=0.29; Figure 4.3A).  There was, however, a trend towards a positive correlation 
between A33 antibodies and neutralisation (p=0.096, r=0.65; Figure 4.3B), indicating that 
some of the neutralising activity may be mediated by antibodies specific for A33.  
 
 
4.3 Cellular responses to MVA 
 
Cellular responses to MVA were measured by the IFN- ELISPOT assay in eight vaccinated 
baboons at multiple time-points pre- and post-MVA vaccination, using cryopreserved PBMC 
samples.  The group included five animals that received three SAAVI DNA-C prime 
vaccinations and two (B524 and B531) or three (B515, B549 and B575) SAAVI MVA-C boost 
vaccinations, and three animals that received two (B533 and B623) or three (B629) SAAVI 
MVA-C vaccinations only.  In four animals, cellular responses were further characterised at 
three time-points by ICS and multiparameter flow cytometry to investigate a broader range of 



















          























































































Figure 4.2 Neutralising antibody responses to MVA.  Eight baboons and 22 macaques were 
immunised with SAAVI MVA-C.  Five baboons and 16 macaques had previously received three 
vaccinations with DNA-C and are represented by closed bars and symbols, while animals that received 
only MVA-C are represented by open bars and symbols.  Neutralising antibody responses are 
expressed as IC50 end-point titres.  The MVA-C vaccinations are represented by black arrows. (A) 
Kinetics of neutralising antibody responses in B623.  (B) Magnitude of neutralising antibody responses 
to MVA in baboons 1 week after the second MVA vaccination.  (C) Magnitudes of neutralising antibody 
responses after the second MVA vaccination in baboons compared to macaques, showing medians and 


















































































Figure 4.3 Relationship between MVA neutralising antibody responses and binding antibody 
responses to the vector.  Eight baboons were immunised with SAAVI MVA-C.  Five of the animals had 
previously received three vaccinations with DNA-C (B515, B524, B531, B549 and B575).  Correlations 
between the neutralising end-point titre 1 week after the second MVA-C vaccination and matching end-
point binding antibody titres to vaccinia capsid proteins B5R (A) and A33 (B) were examined.  
Relationships were determined by Spearman‟s rank correlation. 
 
 
4.3.1 MVA elicits high magnitude IFN- ELISPOT responses 
 
The IFN- ELISPOT assay was used to determine whether T-cell responses were generated to 
the MVA vector. Indeed, strong T-cell responses to MVA were elicited in all eight animals, and 
first detected by 1 week after the first MVA-C vaccination (Figure 4.4A). Responses ranged 
from 318 to 838 net SFU/106 PBMC, with a median of 497 net SFU/106 PBMC.  These 
responses continued to rise 7 weeks later, and were boosted approximately three-fold after the 
second MVA vaccination in all animals, to a median of 1518 net SFU/106 PBMC (range, 728 to 
2762 net SFU/106 PBMC).  Responses were long-lasting, with all animals showing similar or 
higher T-cell responses 12 weeks after the second MVA vaccination (week 61), with a median 
of 1658 net SFU/106 PBMC.  Four animals (B515, B549, B575 and B623) received a third MVA 
vaccination.  Surprisingly, responses were boosted even further, reaching magnitudes of 
between 2772 (B515) and 5245 net SFU/106 PBMC (B549), with a median of 4455 net 
SFU/106 PBMC, 1 week after the third MVA vaccination.  These responses persisted to similar 
or higher frequencies (median 4679 SFU/106 PBMC) at the final time-point assessed, of 8 
months after the third MVA vaccination (week 137).  Thus, T cell responses as measured by 
IFN- release, increased significantly in magnitude with each successive MVA vaccination in all 
eight animals vaccinated (Figure 4.4B). There were no significant differences in magnitudes of 
MVA-specific responses between those animals that had been primed with DNA compared to 













































































Figure 4.4 IFN- ELISPOT responses to MVA.  Eight baboons were immunised with SAAVI MVA-C.  
Five of the animals had previously received three vaccinations with DNA-C (B515, B524, B531, B549 
and B575).  ELISPOT responses are expressed as net spot forming units (SFU)/10
6
 PBMC.  The DNA-
C prime vaccinations are represented by grey arrows and the MVA-C vaccinations by black arrows.  
Four animals (B515, B549, B575 and B623) received a third MVA vaccination. (A) Kinetics of MVA 
responses over the course of the study.  (B) Magnitude of MVA responses 1 week after one, two, or 
three MVA vaccinations. Filled symbols represent DNA-MVA vaccinated animals and open symbols 
indicate animals that received MVA only. Box and whisker plots show medians and ranges.  Significant 
differences detected by the Mann Whitney non-parametric test are shown. ** indicates p<0.01, *** 




















4.3.2 The function and phenotype of MVA-specific T cell responses  
 
Cellular responses detected in the ELISPOT assay were further characterised at three time-
points by ICS and multiparameter flow cytometry to determine further functional 
characteristics, phenotypes and memory differentiation status.  Responses were investigated 
in the four animals that received a third MVA vaccination (B515, B549, B575 and B623), one of 
which received no DNA prime (B623).  Time-points were selected based on sample 
availability, namely 1 week after the second MVA vaccination (week 50), 12 weeks after the 
second MVA vaccination (week 61) and 7 months after the third MVA vaccination (week 135). 
 
MVA-specific responses are predominantly mediated by CD8+ T cells 
 
The magnitudes of the total MVA-specific cytokine responses were determined (including all 
cells secreting one or any combination of IFN-, IL-2 and TNF-).  A representative example is 
shown in Figure 4.5A, indicating the gating strategy used to quantify production of IFN-, IL-2 
and TNF- cytokines by CD4+ and CD8+ T cells in response to MVA.  Cells were gated on 
singlets, lymphocytes, live CD3+, CD4+ and CD8+.  Cytokine responses were elicited by 
CD8+ T-cells in response to MVA, and detected 1 week after the second MVA-C vaccination, 
at a median response of 0.465% (range, 0.059 to 0.95%; Figure 4.5B).  These responses 
increased two-fold in frequency by week 12 following the second MVA vaccination (median 
0.865%, range 0.334 to 1.84%), and a further three-fold (median 2.55%, range 1.831 to 
7.43%) by 7 months after the third MVA vaccination (week 137).  There was a significant 
increase in total cytokine produced by CD8+ T-cells between 1 week after the second MVA 
and 7 months after the third MVA (p=0.029).   CD4+ T-cell responses were detectable but at a 
much lower frequency, except for B575, that had magnitudes ranging from 2.22 to 2.6% over 
the time-points measured.  Figure 4.5C shows that the magnitude of IFN-, IL-2 and TNF-  
produced by CD8+ T-cells increased at each time-point, while cytokine frequencies by CD4+ 
T-cells remained relatively unchanged over the same time period.  Thus, multiple cytokine 
responses are readily elicited in response to MVA, are predominantly mediated by CD8+ T 
cells, and increase in magnitude over successive immunisations. 
 
MVA-specific responses are predominantly CD8-mediated and single cytokine-
producing 
The CD4+ and CD8+ T-cell responses to MVA were further analysed to determine the 
magnitude and proportion of cells producing combinations of IFN-, TNF- or IL-2.  CD8+ T-
cell responses were present in all four animals, reaching high magnitudes (Figure 4.6A; top 








































































































































































































































































































































































Figure 4.5 MVA-specific responses are skewed towards CD8+ T-cells.  Cytokine responses were 
characterised in four baboons that received three MVA-C vaccinations, and IFN-, IL-2 and TNF-α 
responses 1 and 12 weeks after the second MVA-C vaccination, and 7 months after the third MVA 
vaccination, were measured.  (A) Representative flow plots showing gating strategy and CD4+ and 
CD8+ responses, in response to MVA and an unstimulated control.  (B) Total cytokine responses at 
each time-point by CD8+ and CD4+ T-cells.  (C) Total IFN-, IL-2 and TNF-α cytokine responses at 

















CD8+ T-cell responses increased over time, and by 7 months following the third MVA 
vaccination, the cells were producing combinations of three cytokines (IFN-, IL-2 and TNF-), 
two cytokines (IFN- and TNF- or IL-2) or single cytokine (IFN-).  The CD8+ T-cell 
compartment was dominated by single cytokine-producing cells, with IFN- being the 
predominant cytokine produced (Figure 4.6A; bottom panel).  CD8+ T-cells remained 
predominantly single cytokine-producing at all time-points tested, at a mean of 63% of the 
response.  One of the four animals (B575) had high magnitude CD4+ T-cell responses at all 
time-points tested, with the other three animals having detectable but low magnitude 
responses (Figure 4.6B; top panel).  Apart from the high CD4+ responder, and unlike the 
CD8+ T-cell responses, the CD4+ T-cell responses in the remaining animals were relatively 
constant over time.  The CD4+ T-cell response was also dominated by single cytokine 
producing cells, predominantly IL-2 or TNF- (Figure 4.6B; bottom panel).  
 
Memory phenotypes of MVA-specific T-cells  
 
MVA-specific responses were further analysed to investigate the memory differentiation 
phenotype of these cells. CD28 and CD95 were used to differentiate central memory (TCM; 
CD28+CD95+cells) and effector memory (TEM; CD28-CD95+ cells) from naïve T cells 
(CD28+CD95- cells; Sun et al., 2005).  The memory differentiation status of total cytokine 
producing cells (IFN-, IL-2 and TNF-) after MVA stimulation was assessed.  All three 
cytokines were placed on one fluorochrome in the staining panel, as the individual cytokine 
contributions had already been determined using a functional panel, and due to limitations of 
the three-laser LSRII flow cytometer that were used.  Total cytokine responses measured by 
the two panels correlated closely (p=0.0013, r=0.83 and p=0.0016, r=0.82, for the CD4+ and 
CD8+ responses, respectively; data not shown).   
 
Cells were gated on singlets, lymphocytes, live CD3+, CD4+ and CD8+, and cytokine-
producing cells were then overlaid onto the memory populations to determine their distribution 
within the different memory subsets (Figure 4.7A).  As reported above, CD8+ T-cells increased 
in magnitude at each time-point (Figure 4.7B).  For example, B515 showed low levels MVA-
specific CD8+ T-cells 1 week after the first MVA vaccination (0.2%).  This increased by 12 
weeks after the second MVA vaccination (0.5%), and increased even further by 7 months 
following the third MVA vaccination, to 2.6%.  The other three animals followed a similar 
pattern.  CD4+ T-cell responses were generally of lower magnitude than CD8+ responses, with 
the exception of B575, as reported above (Figure 4.7B).  In B549, MVA-specific CD4+ 
responses were not detected until 7 months after the third MVA.  CD8+ T-cell responses to 

















and these proportions changed little over time as the response increased, with a mean of 
50.5% of CD8+ cells being TCM.  MVA-specific CD4+ T-cells were almost exclusively TCM in 
animals with detectable cytokine (Figure 4.7C, bottom panel), with a mean of 91% TCM over the 
three time-points.  In fact, in all three animals with detectable CD4+ responses at the earlier 
time-points, the proportion of MVA-specific TEM made up less than 5% of the CD4+ response, 
and this increased to 22% in these animals by 7 months after the third MVA vaccination.  
 
These data reveal that cellular responses to MVA were predominantly CD8+ IFN-+ cells, 
distributed evenly between TCM and TEM subsets, with lower magnitude single cytokine CD4+ 




4.4 The influence of MVA-specific cellular and humoral immunity 
on cellular responses to HIV antigens 
 
The humoral and cellular responses to MVA described above were compared to the HIV-
specific responses that were generated in the same animals, reported previously (Burgers et 
al., 2009), in order to determine whether vector-specific responses limited response to the HIV 
immunogens that the vector expressed, in the context of successive vaccinations.  These 
comparisons focused on vaccinated baboons, but since neutralising antibody responses were 
also measured in vaccinated macaques, these data are also presented.  Unpublished HIV-
specific responses in macaques were provided by Dr Wendy Burgers. 
 
4.4.1 Cellular responses to HIV in response to DNA-MVA vaccination 
 
HIV-specific responses measured by IFN- ELISPOT in baboons to the vaccination regimen 
are shown in Figure 4.8.  HIV-specific responses to DNA priming were undetectable.  
However, at week 42, one week after the first MVA boost, four out of five animals that had 
been primed with DNA responded vigorously (B515, B524, B549 and B575).  These responses 
ranged from 2357 to 5970 net SFU/106 PBMC per animal (median 2575 SFU/106 PBMC).  
Responses waned, but were then boosted by one week after the second immunisation, 
ranging from 320 to 4452 net SFU/106 PBMC per animal (median 2352 SFU/106 PBMC).  In 
three of these four animals (B524, B549, B575), the peak response after the second MVA 
vaccination was lower than that after the first MVA vaccination, with a median of 1399 SFU/106 
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Figure 4.6 Functional nature of MVA cellular responses IFN-, IL-2 and TNF-α cytokine responses were characterised in four baboons by multiparameter 
flow cytometry at 1 and 12 weeks after the second MVA-C vaccination and at seven months after the third MVA-C vaccination.  Magnitude (top panel) and 
proportion (bottom panel) of cytokine responses generated by CD8+ T-cells (A) and CD4+ T-cells (B).  Lines represent medians and one, two or three 
functions are repre ented by pink, green and purple respectively.   
• 
• 





















































































































































Figure 4.7 Memory phenotype of MVA-specific T-cell responses.  
Memory phenotypes of MVA-specific cells were characterised by 
multiparameter flow cytometry in four baboons at 1 and 12 weeks after 
the second MVA-C vaccination and at seven months after the third 
MVA-C vaccination.  (A) Representative flow plots showing gating 
strategy in an MVA stimulated animal and a negative control.  Total 
cytokine produced (left panel) is overlayed onto the right panel showing 
central memory and effector memory contribution to cytokine 
production.  (B) Total cytokine responses in each of the four animals 
showing CD8+ and CD4+ T-cells at each time-point.  (C) Proportion of 
central memory (TCM) and effector memory (TEM) CD8+ and CD4+ T-
cells at each time-point.  Mean responses are represented for the 
number of animals indicated. TCM responses are shown in dark blue 

















One animal (B531) that was primed with DNA did not mount any response to the HIV antigens 
in the vectors.  Four animals went on to receive a third MVA vaccination almost a year later.  
Here, it was interesting to note that responses were boosted to peak responses higher than 
those after the first or second MVA vaccination, ranging from 2340 to 7640 net SFU/106 PBMC 
per animal (median 4459 SFU/106 PBMC; Figure 4.8B). HIV-specific responses were 
significantly higher in animals receiving a DNA prime compared to animals that received MVA 
only (p=0.0475, Figure 4.8C), indicating clearly that although DNA-priming did not elicit 
measurable responses, a robust priming of HIV responses occurred. 
 
Thus, MVA vaccinations given in close succession did not appear to boost responses to HIV 
antigens higher than previous peaks, whilst anti-HIV responses are boosted when MVA was 
given one year after the previous MVA vaccination.  HIV-specific responses measured in 
macaques that were primed with DNA showed similar kinetics and magnitudes, reaching a 
median of 1399 SFU/106 PBMC after the first MVA-C vaccination following DNA priming, 
waning and being boosted after the second MVA-C to levels not higher than those after the 
first (median 839 SFU/106 PBMC; data not shown).  MVA-only animals had low magnitude 
responses that were detected in two of the six animals 1 week after the first MVA. 
 
 
4.4.2 The effect of vaccinia virus A33 and B5R binding antibody responses on 
HIV-specific responses 
 
As described in section 4.2.1, antibody responses were generated to A33 and B5R capsid 
proteins of MVA in baboons.  There were strong A33 and lower B5R responses that peaked 
after the second MVA vaccination and subsequently waned rapidly.  These were boosted by 
the third MVA vaccination to levels not higher than those after the second MVA vaccination.   
 
The magnitude and kinetics of MVA capsid binding antibodies were compared to HIV-specific 
cellular responses, in order to determine whether they might be inhibiting the latter responses. 
The kinetics of HIV cellular responses and MVA-specific A33 and B5R binding antibody 
responses were investigated in each animal (Figure 4.9). Apart from the single DNA-MVA HIV 
non-responder, cellular responses to HIV were present in all these animals prior to the 
development of A33 and B5R antibodies to MVA.  In fact, the MVA binding antibodies reached 
their peak only after the second MVA vaccination.  Thus, it is very likely that if MVA-specific 
antibody responses would have any effect on HIV-specific responses, this would come into 
play only at the second and third MVA vaccinations, when “pre-existing” antibodies as a result 







































































































Figure 4.8 IFN- ELISPOT responses to HIV vaccine antigens.  Eight baboons were immunised with 
SAAVI MVA-C.  Five of the animals had previously received three vaccinations with DNA-C (B515, 
B524, B531, B549, B575).  ELISPOT responses are expressed as net spot forming units (SFU)/10
6
 
PBMC.  The DNA-C prime vaccinations are represented by grey arrows and the MVA-C vaccinations by 
black arrows.  Four animals (B515, B549, B575, and B623) received a third MVA-C vaccination. (A) 
Kinetics of total magnitude of IFN- ELISPOT responses.  (B) Total magnitude of responses 1 week 
after one, two, or three MVA-C vaccinations.  (C)  Total magnitude of responses 1 week after one, two 
or three MVA-C vaccinations comparing animals that received a DNA prime with those that did not.  
Filled symbols represent DNA-MVA vaccinated animals and open symbols indicate animals that 

















The kinetics of HIV responses in non-primed MVA-only animals differed substantially.  Here, 
responses to HIV were being generated at the same time as responses to MVA, as there was 
no “advantage” of previous priming.  While it may be tempting to speculate that this gave rise 
to the lower HIV-specific responses observed in these three animals (B533, B623, B629), an 
equally likely explanation is that the HIV antigens expressed by the MVA construct are poorly 
immunogenic in the absence of DNA priming. HIV-specific responses were boosted in the 
presence of titres of MVA binding antibodies of 40 to 80 at the second or third MVA vaccination 
in animals B515 and B549; conversely, in animal B524, HIV-specific responses were boosted, 
but not to levels higher than after the first MVA vaccination, in the presence of an A33 titre of 
320 on the day of vaccination. 
 
The relationship between MVA-specific antibody and HIV-specific cellular responses was 
examined using Spearman‟s rank correlation, 1 week after the second and third MVA-C 
vaccinations.  When responses in DNA-MVA and MVA-only animals were examined together, 
no significant relationships were found (p=0.27, r=-0.34 and p=0.22, r=-0.38 for B5R and A33, 
respectively; data not shown).  Since the kinetics of HIV-specific responses was different in 
these two groups of animals, relationships were investigated separately.  Interestingly, there 
was a trend towards an inverse correlation between B5R antibody responses and HIV-specific 
cellular responses in those animals that had been primed with DNA (p=0.06, r=-0.72; Figure 
4.10A), but not in the MVA-only animals (p=0.33, r=0.83; Figure 4.10B), although the few data 
points for the latter group may preclude robust statistical analysis.  There was no correlation 
between A33 responses and HIV-specific cellular responses in either group (Figure 4.10C and 
D). 
 
4.4.3 The relationship between neutralising antibody responses to MVA and 
HIV-specific responses 
 
Neutralising antibody responses to MVA were measured 1 week after the second MVA boost 
in eight baboons and 22 macaques. The relationship between neutralising antibody end-point 
titres and HIV-specific cellular responses at the same time-point were examined.  Interestingly, 
there was a trend toward an inverse correlation between neutralising antibodies to MVA and 
HIV-specific T cell responses in baboons primed with DNA (p=0.08, r=-0.89; Figure 4.11A), 
indicating that neutralising antibodies generated to MVA may be having an effect on HIV-
specific cellular responses, although few data points were available for this analysis.  No such 
relationship was evident for those that received MVA only (p=0.33, r=1; Figure 4.11B), 























































































































































































Figure 4.9 Binding antibody responses to vaccinia envelope proteins and IFN- ELISPOT responses to HIV.  Eight baboons were immunised with 
SAAVI MVA-C.  Five of the animals had previously received three vaccinations with DNA-C (B515, B524, B531, B549, B575).  ELISPOT responses are 
expressed as net spot forming units (SFU)/10
6
 PBMC, and binding antibody responses as end-point titres.  The DNA-C prime vaccinations are represented by 
grey arrows and the MVA-C vaccinations by black arrows.  A33 and B5R antibody responses are represented in dark blue and light blue respectively, and 
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Figure 4.10 Effect of binding antibody responses to MVA on IFN- ELISPOT T-cell responses to 
HIV antigens expressed by the vector.  Eight baboons were immunised with SAAVI MVA-C.  Five of 
the animals had previously received three vaccinations with DNA-C (B515, B524, B531, B549 and 
B575).  Four animals (B515, B549, B575, and B623) received a third MVA-C vaccination. Correlations 
between the total magnitude of HIV-specific T-cell responses 1 week after the second and third MVA-C 
vaccinations and matching end-point binding antibody titres to vaccinia capsid proteins B5R (A and B) 
and A33 (C and D) were examined.  (A) and (C) show responses in DNA-MVA vaccinated animals, and 




The relationship was therefore examined in macaques, where sixteen animals received DNA-
MVA and six received MVA only, and MVA-specific neutralising antibodies were of higher titres 
than in baboons. There was however no detectable influence of MVA-specific neutralising 
titres on HIV-specific cellular responses in those animals primed with DNA (p=0.49; r=0.2; 
Figure 4.11C) or not (p=1, r=0; Figure 4.11D).  Thus, although there was a trend for lower HIV-
specific responses the higher the MVA neutralising antibodies in 5 DNA-MVA vaccinated 
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Figure 4.11 Effect of neutralising antibody responses to MVA on IFN- ELISPOT T-cell responses 
to HIV antigens expressed by the vector.  Eight baboons and twenty two macaques were immunised 
with SAAVI MVA-C.  Five of the baboons and sixteen of the macaques had previously received three 
vaccinations with DNA-C. Correlations between the total magnitude of HIV-specific T-cell responses 1 
week after the second MVA-C vaccination and matching end-point neutralising antibody titres to MVA in 
baboons (A and B) and macaques (C and D) were examined.  (A) and (C) show responses in DNA-
MVA vaccinated animals, and (B) and (D) shows animals that received MVA only.  Relationships were 
determined by Spearman‟s rank correlation. 
 
 
4.4.4 MVA-specific cellular responses do not affect HIV cellular responses 
 
Since no convincing relationship between MVA-specific antibody responses and HIV-specific 
responses was detected, I next investigated whether the MVA-specific cellular response may 
have had an influence on the HIV-specific response.  Comparisons of the total IFN- ELISPOT 
response to HIV antigens and MVA are shown for individual animals in Figure 4.12.  After the 
first MVA boost, four of five DNA primed animals generated T-cell responses to HIV, ranging 

















animals.  Two of the four DNA-MVA responders had higher magnitude peak responses to HIV, 
whilst the other two had higher magnitude peak responses to MVA.  In all three animals that 
received MVA only, the MVA-specific responses were of greater magnitude than the HIV-
specific responses, at all time-points.  It was interesting to observe that in animal B531, where 
no HIV-specific responses were detected, that there was a robust response to MVA, indicating 
that the vaccine did „take‟.  The kinetics of the responses differed dramatically.  Whilst the HIV 
responses contracted by an average of 64%, to 1230 SFU/106 PBMC by 8 weeks following the 
first MVA, and in three of the four DNA-MVA responders were boosted to lower than peak after 
the second MVA, MVA-specific responses were boosted to higher levels.  In fact, in all of the 
animals except B629, they did not contract and steadily increased over time.  After the third 
MVA vaccination, both HIV and MVA responses expanded dramatically, to peak levels higher 
than previously generated. The MVA responses were highly stable over time, and in two of the 
four animals (B549 and B524) appeared to still be increasing 7 months after the third MVA.  
 
Spearman‟s rank correlation was performed to determine whether the strong MVA-specific 
cellular responses had any effect on the HIV-specific responses.  There was a weak but 
significant positive correlation between HIV and MVA-specific cellular responses (p=0.03, 
r=0.5; Figure 4.13), indicating that higher vector-specific cellular responses may result in 
higher HIV responses.  In other words, immunogenic vectors may lead to immunogenic vector-
encoded antigen responses. 
 
4.4.5 Functional responses to MVA are dominated by single cytokine-producing 
cells, whereas responses to HIV show greater heterogeneity 
 
It was of interest to compare the nature of the responses elicited to the vector, compared to the 
HV antigens it encoded.  Four animals were studied at three time-points to determine the 
polyfunctionality of responses elicited to MVA compared to HIV.  The time-points tested were 
at 1 and 12 weeks following the second MVA vaccination, and at the final time-point of 7 
months following the third MVA vaccination.  T-cell responses to MVA were dominated by 
single cytokine-producing cells (discussed in section 4.3.2), whereas HIV-specific T-cell 
responses had a much larger proportion of cells producing two or three cytokines at each of 
the three time-points tested, irrespective of whether they received a DNA prime (Figure 4.14A) 
or not (Figure 4.14B).  This observation was true for both CD8+ and CD4+ T-cell responses.  
As for MVA-specific responses, there were no changes in the functional repertoire of cytokines 
produced over time in HIV-specific T cells.  Thus, HIV-specific responses were more 
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Figure 4.12 IFN- ELISPOT responses to MVA and HIV.  Eight baboons were vaccinated with SAAVI MVA-C.   Five of the animals had previously received 
three vaccinations with DNA-C (B515, B524, B531, B549, B575).  ELISPOT responses are expressed as net spot forming units (SFU)/10
6
 PBMC.  The DNA-
C prime vaccinations are represented by grey arrows and the MVA-C vaccinations by black arrows. MVA responses are represented in blue and HIV-specific 
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Figure 4.13 Effect of IFN- ELISPOT T-cell responses to MVA on ELISPOT T-cell responses to HIV 
antigens expressed by the vector.  Eight baboons were vaccinated with SAAVI MVA-C.  Five of the 
animals had previously received three vaccinations with DNA-C (B515, B524, B531, B549, B575).  
ELISPOT responses are expressed as net spot forming units (SFU)/10
6
 PBMC.   Four animals (B515, 
B549, B575, and B623) received a third MVA-C vaccination. Total magnitude of responses 1 week after 
one, two, or three MVA-C vaccinations to MVA were correlated with total T-cell responses to HIV.  .  
Relationships were determined by Spearman‟s rank correlation. 
 
 
There were no significant differences in the levels of IFN-, IL-2 and TNF- produced by CD4+ 
and CD8+ T-cells responding to MVA compared to HIV, when grouping the three time-points 
tested (Figure 4.15A).  However, IFN- responses produced by MVA-specific CD8+ T-cells had 
a median two-fold greater magnitude (median 1%) than those produced by HIV-specific CD8+ 
T-cells (median 0.5%), although this was not significant, probably owing to the small number of 
samples.  Additionally, although TNF- responses were of low magnitude,  HIV-specific CD8+ 
T-cells produced greater than two-fold higher responses (median 0.5%) compared to those by 
MVA-specific CD8+ T-cells (median 0.2%), although this was not significant.  
 
Proportionally, CD8+ T-cells responded to MVA and HIV differently when total responses over 
time were considered (Figure 4.15B), with IFN-  levels making up 71% of the total response to 
MVA compared to 42% of the total response to HIV.  IL-2 responses were similar, however 
TNF- contributed 41% to the total cytokine response to HIV compared to only 15% to MVA.   
The total proportions of IFN-, IL-2 and TNF- responses elicited by CD4+ T-cells were almost 
identical, with the highest proportion of cells producing TNF- of 66% in response to MVA and 

























Figure 4.14 Polyfunctionality of cytokine responses to MVA and HIV. IFN-, IL-2 and TNF-α 
responses were measured by multiparameter flow cytometry at 1 week and 12 weeks after the second 
MVA-C vaccination and at 7 months after the third MVA vaccination in four animals.  Proportions of one, 
two or three cytokine-producing cells were determined.  (A) MVA-specific polyfunctional responses 
generated by CD8+ T-cells (top row, left panel) and CD4+ T-cells (bottom row, left panel) compared to 
HIV-specific responses in animals that received MVA and DNA primes (right panel, B515, B549, B575).  
(B) MVA-specific median IFN-, IL-2 and TNF-α cytokine responses generated by CD8+ T-cells (top 
row, left panel) and CD4+ T-cells (bottom row, left panel) compared to HIV-specific responses in  the 
baboon that received MVA only (right panel, B623).  One, two or three cytokine-producing cells are 
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Figure 4.15 Frequency of cytokine responses to MVA and HIV. IFN-, IL-2 and TNF-α responses 
were characterised in four animals by multiparameter flow cytometry at 1 and 12 weeks after the second 
MVA-C vaccination and at 7 months after the third MVA vaccination. (A) MVA-specific median IFN-, IL-
2 and TNF-α cytokine responses compared to HIV-specific responses elicited by T-cells. MVA 
responses are represented by blue bars, and HIV responses by red bars.  Combined proportions of 
MVA-specific median IFN-, IL-2 and TNF-α cytokine responses compared to HIV-specific median 




















4.4.6 Phenotypic responses to MVA are identical to those of HIV 
 
It was of interest to compare the memory profiles of HIV-specific and MVA-specific responses. 
Four animals were studied at three time-points to determine the phenotype of cytokine 
responses elicited to MVA compared to HIV.   At 1 week after the second MVA vaccination, 
there was a significant difference between TCM and TEM proportions of CD8+ T-cells (Figure 
4.16A), with TCM making up a significantly higher (p=0.03) and TEM a significantly lower 
(p=0.03) proportion of CD8+ T cells specific for HIV compared to MVA.  At the later time-
points, responses to HIV and MVA were similar, with balanced proportions of TCM and TEM 
cells.  The proportions of CD4+ T-cell responses to MVA and HIV were similar (Figure 4.16B), 
and were dominated by central memory T-cells, with mean of 97% for the two time-points after 
the second MVA vaccination, and 70% at 7 months after the third MVA vaccination.  Thus, the 
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igure 4.16 MVA-specific phenotype responses and their comparison to HIV-specific responses. 
Memory phenotypes of MVA-specific cells were characterised by multiparameter flow cytometry in four 
animals at 1 and 12 weeks after the second MVA-C vaccination and at 7 months after the third MVA-C 
vaccination.  MVA-specific CD4+ T-cell responses ( ) and CD8+ T-cell re ponses (B) showing 
proportions of central memory and effector memory at each time-point.  MVA responses are represented 



















MVA-specific responses generated in a small group of eight baboons that had been vaccinated 
with candidate DNA-MVA HIV vaccines were assessed, to determine whether anti-vector 
cellular and humoral immune responses could be detected, and what effect, if any, they had on 
the generation or boosting of responses to the HIV antigens expressed by the vectors.  Limited 
analysis was also performed in 22 macaques that received a similar vaccine regimen. 
 
Binding antibody responses to vaccinia virus envelope proteins A33 and B5R and MVA-
specific neutralising antibodies were generated, however these had no clear effect on the 
generation or boosting of T-cell responses to the HIV antigens in the vaccine.  Strong cellular 
responses to MVA were identified by IFN- ELISPOT, and although these responses were 
long-lasting and boosted to higher levels by each subsequent MVA vaccination, high 
magnitude cellular responses to the HIV antigens were elicited in most animals.  Indeed, even 
in an environment of strong anti-vector cellular responses, HIV responses were boosted.  
Cellular responses to HIV showed greater polyfunctionality than MVA responses, and memory 
subsets generated were similar for HIV and MVA-specific T cells responses.  Thus, it appears 












































Viral vectors are proving to be important vehicles for recombinant vaccines against some of 
the most important pathogens, such as HIV and TB.  A challenge with the use of these 
complex viruses is that anti-vector immune responses can potentially dampen the immune 
response to the vaccine antigens they express, by rapid clearance of the vaccine vector and 
thus shorter duration of antigen exposure to T cells (as reviewed by Duerr et al., 2006).  
Indeed, the effect of anti-vector immunity has been recently highlighted by findings from the 
STEP trial, where uncircumcised men with pre-existing Ad5 immune responses showed 
increased acquisition of HIV after vaccination with an Ad5-vectored HIV vaccine (McElrath et 
al., 2008).  A further issue is that immunity to an HIV vaccine may wane over time, and may 
need to be boosted again at a later stage with the same vector, in the presence of immunity 
that developed at the first vaccination.  Thus, both existing anti-vector immunity from natural 
infection, or from previous vaccination with the same recombinant vector, may be a challenge 
for vaccines.   
 
This study aimed to determine whether vector responses in eight baboons vaccinated with an 
HIV candidate vaccine, consisting of a DNA prime and MVA boost vaccine regimen could be 
detected, if they persisted, and if after multiple vaccinations with MVA there was an effect on 
immunity to the HIV antigens they expressed.  These vector-specific responses were 
compared to previously published HIV-specific cellular and humoral responses in the same 
animals (Burgers et al., 2009).  The major findings were as follows:  (1) Both humoral and 
cellular vector-specific responses could indeed be detected in all vaccinated baboons; (2) 
Binding antibody responses to vaccinia virus membrane proteins A33 and B5R reached peak 
titres one week after the second MVA vaccination.  They were of short duration, and even 
though they were boosted by the third MVA, waned rapidly.  There was no correlation between 
these responses and HIV-specific cellular responses, or HIV envelope gp120 antibody 
responses; (3) Neutralising antibodies to MVA were detected in all animals at one week after 
the second MVA vaccination, but there was no correlation between their titres and the HIV-
specific humoral or cellular responses; this analysis included 22 macaques that were 
immunised with a similar vaccine regimen, and similarly, no relationship was found between 
MVA-specific neutralising titres and HIV-specific cellular responses; (4) Robust IFN-γ 
responses to MVA were readily detectable by ELISPOT after the first MVA vaccination.  These 

















There was no correlation between MVA-specific cellular responses and HIV-specific cellular 
responses;  (5) Analysis in a subset of animals revealed that the cellular responses to MVA 
were dominated by CD8+ T-cells producing mainly IFN- alone, while HIV-specific responses 
showed greater heterogeneity, with more cells producing two or three cytokines 
simultaneously by both CD4+ and CD8+ T-cells;    (6) Finally, there were no differences in the 
T cell memory phenotypes of responses generated to MVA and HIV, with CD4+ T cells falling 
predominantly within the central memory subset and CD8+ T cells distributed evenly between 
central and effector memory subsets.  
 
Although not an issue that the present study dealt with, prior immunity to MVA may be as a 
result of prior vaccination against smallpox, with vaccinia virus.  Smallpox vaccination was 
halted in 1971 in the UK, 1972 in the US and 1979 in South Africa, and smallpox was declared 
eradicated by the World Health organisation in 1980 (Strassburg et al., 1982).  Thus, most 
people over the age of 32 in South Africa will have been vaccinated against smallpox.  Thus, 
many older individuals (and also some laboratory and healthcare workers) will have pre-
existing immunity to vaccinia virus that may influence the efficacy of an MVA-vectored HIV 
vaccine.  Hammarlund et al. (2003) reported that over 90% of individuals that were vaccinated 
with vaccinia virus between 25 and 75 years before still had detectable humoral and cellular 
immune responses.  In fact, humoral responses were very stable over time, detectable up to 
75 years after vaccination.  T-cells responses were not as long lasting with a half-life of 8 to 15 
years.  Interestingly, neutralising antibody titres > 1:32 were protective against smallpox.  In 
the present study, neutralising titres of >1:40 were detectable in all animals studied; they did 
not, however, appear to dampen vector-induced responses.   
 
Lower MOI were found to be better than higher MOI for detecting cellular responses, and 
therefore extensive optimisation was performed for all assays.   MVA has been shown to result 
in necrosis and apoptosis of immature dendritic cells in humans at high MOI due to 
cytopathogenic effects, with lower MOI more efficiently infecting the cells (Kastenmuller et al., 
2006).  This has also been shown recently in a murine model (Norder et al., 2010) where an 
MOI of 0.5 was shown to be more infective than an MOI of 5. In studies using human PBMC, a 
range of MOI have been used, from as low as 0.1 (Cosma et al, 2007), through an 
intermediate of 1.0 (Smith et al., 2005; Howles et al., 2010) and up to 10 (Speller and Warren, 
2002).  This highlights the need for optimisation to be carried out specific to the species and 
MVA that are being used.  Relatively low MOIs may be required in baboons, and titrations 


















Binding antibody responses to MVA were measured.  Peak binding antibody responses of 
short duration were detected to the extracellular enveloped virion proteins (EEV) A33 and B5R 
after the second MVA vaccination, but not to the intracellular mature virion proteins (IMV), L1R 
and A27.  Previous studies in monkeys have shown detectable MVA-specific binding 
antibodies after vaccination with MVA, however, the timing, specificity and duration of 
responses vary greatly.  Earl et al. (2004) showed detection of durable A33, B5R and L1R 
responses after the first MVA vaccination, and subsequent boosting to higher levels after the 
second MVA.  Binding antibody titres to MVA are generally lower than those generated by 
replication competent vaccinia virus (Sharpe et al., 2001).  Studies in humans have confirmed 
differing detection of antibody titres depending on the route and dose of MVA vaccination, with 
higher titres elicited when higher doses of MVA are delivered, irrespective of the route (Wilck 
et al., 2010; Parrino et al., 2006), although it does appear that higher doses delivered 
intramuscularly as opposed to intradermally elicit higher binding antibody responses (Currier et 
al., 2010).   Interestingly, in these studies it was found that anti-A27 responses are low or 
undetectable, which has also been described in macaques vaccinated with MVA (Grandpre et 
al., 2009).  This may mean that anti-A27 antibody responses are lacking in response to certain 
attenuated vaccinia strains, possibly due to lower levels of A27 expression (Wilck et al., 2010).  
Anti-L1R responses were more widely described, but at least one study in humans found no 
responses to L1R (Parrino et al., 2006).  Poxvirus purification processes only treat the virus 
particles packaged within a cell (IMV) and EEV particles are shed into the culture medium and 
discarded (Malarme et al., 2010).  EEV and IMV forms of the virus are both infectious, with 
IMV located in the cytoplasm of infected cells, while EEV are IMV surrounded by an extra 
membrane (Earl et al., 2004).  MVA is infectious but cannot replicate in most primary 
mammalian cells as there is a block in late gene expression.  A33 and B5R are expressed 
early and late in infection, while L1R and A27, which are required for cell entry and membrane 
fusion, are expressed only late in infection (Coulibaly et al., 2005).  The MVA used in our 
candidate vaccines was likely only IMV, which infected cells and early gene expression would 
have commenced, thus A33 and B5R responses were detected.  It may be possible that the 
point at which the transcriptional block occurs in late expression varies between different 
recombinant MVA strains, and L1R and A27 expression was minimal or absent, which may 
explain why antibodies were not detected in this study.  
 
This study showed no relationship between binding antibody responses and the HIV-specific 
cellular or humoral response, irrespective of DNA priming, although there was a trend towards 
an inverse correlation between B5R titres and HIV-specific cellular responses that did not 
reach significance (p=0.06).  Perhaps a larger study would resolve this relationship.  

















existing vaccinia antibodies decreased SIV-specific cellular responses but not humoral 
responses, but this was in animals that were vaccinated with vaccinia 17 months prior to the 
first DNA prime.  However, in humans it has been shown that pre-existing vaccinia antibodies 
can decrease both HIV-specific cellular and humoral responses (Gudmundsdotter et al., 2009).  
It is important to consider there may be additional functions of antibodies other than 
neutralisation that could contribute to reducing the vaccine inoculum and therefore the 
responses to the transgenes.  Evidence for this is suggested by the modest success of the 
RV-144 trial, where canarypox expressing HIV genes was tested (Rerks-Ngarm et al., 2009).  
There was no association between the protection conferred by the vaccination regimen and 
the T-cell responses or production of neutralising antibodies, although antibodies to HIV Env 
were present.  It may be possible that protection was mediated by other functions of antibody, 
such as antibody-dependent cellular cytotoxicity (ADCC) activity.  ADCC-capable antibodies 
can bind virus and form immune complexes, resulting in clearance of the virus by natural killer 
cells before infection could take place.  It would be of interest to examine the sera from 
animals in my study to determine whether any of the vector-specific antibodies have other 
functions, such as ADCC activity, that would clear (or reduce) the vaccine inoculum before an 
immune response could be elicited.  
 
Neutralising antibodies to MVA were detected in all animals after the second MVA vaccination, 
however these titres did not correspond with capsid binding antibody titres detected.  It is 
important to note the difference in assay antigens used, where the binding antibodies were 
determined in response to a few vaccinia membrane proteins, and the neutralising antibodies 
to whole MVA virus. Vaccinia has a range of capsid proteins such as H3L, D8L, and A28L 
which have been implicated in binding and entry of vaccinia virus strains into cells (Carter et 
al., 2005).  It is thus possible that capsid proteins other than the ones tested for led to the 
production of neutralising antibodies (Berhanu et al., 2008; Davies et al., 2005; Nelson et al., 
2008).  It may be important to further characterise humoral responses elicited by MVA to a 
broader range of vaccinia virus proteins (Wilck et al., 2010).  Interestingly, the levels of 
neutralising antibodies in macaques were significantly higher than those in baboons, which is 
possibly as a result of the combination of vaccine dose and animal weight, as all the animals 
received 109 pfu/ml of vaccine, and the macaques weigh an average of between 5.34 kg 
(female) and 7.7 kg (male), whereas baboons weigh between 15 kg (female) and 33 kg (male).  
The presence of neutralising antibodies in the eight baboons and 22 macaques however had 
no effect on the HIV-specific cellular or humoral responses.  In a recent macaque study, 
vaccinia-specific neutralising antibodies did show an inverse correlation with SIV-specific CD8 
T-cells after the second MVA boost, but did not have an effect on SIV-specific antibody 


















Robust MVA-specific cellular responses were elicited by the first MVA vaccination.  They were 
boosted to significantly higher magnitudes after each MVA vaccination and were long lasting.  
Despite their high magnitudes there was no relationship between these responses and 
responses to the HIV inserts, even though by the third MVA vaccination, the MVA-specific 
cellular responses out-grew the HIV-specific cellular responses, in three of the five animals 
that received DNA and MVA.  In other non-human primate studies, MVA also resulted in 
cellular responses after the first vaccination, however there were no differences between the 
first and second vaccinations (Earl et al., 2004).  This may possibly be due to a lower dose of 
MVA having been used (108).  Human studies have reported strong and durable MVA-specific 
responses that are boosted by subsequent vaccinations (Smith et al., 2005; Currier et al., 
2010; Precopio et al., 2007).  These studies suggest that vaccinia responses are always 
immunodominant when used as a vector, and that priming of responses, for example by DNA, 
is required.  Interestingly a recent study in humans found that vaccinia-specific T-cells were 
significantly lower in those receiving the DNA prime compared to those receiving MVA only 
(Goepfert et al., 2011).  These authors suggested that DNA priming may limit anti-MVA 
responses, however this was not evident from my study.  I found no difference between MVA-
specific responses when comparing those baboons that were primed with DNA to those that 
were not.  Further studies with greater animal numbers would shed more light on this issue.  
Few studies have directly compared vector-specific and HIV insert-specific responses to 
determine the impact, if any, of vector-specific cellular responses on HIV cellular responses.  
The focus tends to be on whether vector-specific antibodies impact on the production of insert-
specific responses, as antibody responses are the most likely to limit the vector inoculum.  
However, consistent with the results of my study, Howles et al. (2010) showed that MVA-
specific cellular responses generated by a DNA-MVA prime boost regimen in humans had no 
effect on HIV-specific cellular responses. 
 
The MVA-specific cellular responses were dominated by CD8+ T-cells that produced mainly 
IFN-, in addition to a small number of polyfunctional cells producing combinations of IFN-, IL-
2 and TNF-α.  HIV-specific responses were evenly distributed with polyfunctional CD4+ and 
CD8+ T-cells producing two or more combinations of IFN-, IL-2 and TNF-α.  Polyfunctional 
responses have been shown to mediate protection against some pathogens (Darrah et al., 
2007) and may be important in control of HIV replication (Betts et al., 2006).  It is possible that 
the largely monofunctional response to MVA in my study is the reason that there was no effect 
on the immune response to the HIV inserts.  MVA vaccine has previously been shown to elicit 

















elicited to vaccinia virus and MVA (Precopio et al., 2007).  Cells were capable of producing up 
to five cytokines (IFN-, IL-2, TNF-α, MIP-1β and CD107a) simultaneously.  Of course, I 
cannot exclude the possibility, having only measured three cytokines, that MVA-specific cells 
were not producing a range of additional cytokines, as well as cytotoxic molecules.  A wide 
range of different cytokines are produced in response to other vectors (Pine et al, 2011), and 
this may be true for MVA also. 
 
This study found no differences in the memory phenotypes of MVA and HIV responses, with 
cytokine producing CD4+ T cells being predominantly central memory and CD8+ cells showing 
a balance between central and effector memory subsets.  It has been previously described 
that MVA primed a predominantly central memory response to the HIV inserts it encoded 
(Pillai et al., 2011).  CD8+ T-cells to MVA in humans have been described as having an 
unusual phenotype, consisting of cells expressing both CD45RA and CD27, indicating a naive 
population of cells (Precopio et al., 2007).  CD27 expression was however dimmer than 
expected in a true naive population, and it seems MVA-specific T-cells are phenotypically 
unique.  These were however long-lived, with responses detected 5 years later in one 
individual.  In a recent study in mice, it was shown that MVA vaccination results in the rapid 
formation of central memory cells as early as two weeks after vaccination (Reyes-Sandoval et 
al., 2011).  The implications of a predominantly central-memory skewed response for HIV 
vaccine protection are not fully known.  
 
This study observed strong HIV-specific immune responses despite the presence of vector-
specific cellular or humoral responses.  However, one issue that was not determined was 
whether the responses to HIV may have been even higher had there been no immunity to the 
MVA vector.  In light of the fact that MVA elicits such strong immune responses that are often 
immunodominant (Smith et al., 2005), genetic engineering of MVA may be one way to reduce 
anti-vector immunity.  Garber et al. (2009) constructed a less antigenically complex MVA by 
deleting structural genes.  They showed, using this construct as a vector for HIV Gag, that 
fewer vector-specific CD8+ T-cell responses and significantly higher Gag-specific responses 
were elicited in mice and macaques compared to the parental vector.  
 
There were several limitations to this study.  Firstly, it was difficult to draw conclusions from 
direct comparison between the magnitude of cellular responses to HIV and MVA, because 
antigen stimulation in the ELISPOT assays differed.  Stimuli for HIV antigens were overlapping 
peptides, whilst MVA ELISPOT assays used whole virus as stimulation.  Peptides do not need 
processing to be presented by antigen presenting cells, while whole MVA virus needs to infect 

















breadth of responses detected to MVA.  Indeed, Smith et al. (2005) found higher MVA-specific 
responses when using single MVA epitopes, than when using whole MVA in ELISPOT assays.  
However, Howles et al. (2010) found a strong correlation between responses generated to 
whole MVA virus and vaccinia virus peptides by IFN- ELISPOT.  Secondly, the animals in our 
study were not challenged, so even though we did not show a detectable effect of vector-
specific immune responses on the HIV-specific responses, anti-vector responses could not be 
compared with protection from challenge, and it is thus impossible to know whether vaccine-
induced responses could provide protection from disease or lead to control of viraemia.  
Indeed, even if there was an effect of vector responses on HIV-specific responses, there may 
have been no difference upon challenge, as observed by Kannanganat et al. (2010). Here, 
vaccinia-immune macaques with low SIV-specific cellular responses in the presence of strong 
anti-vector CD8+ T-cell responses and neutralising antibodies exhibited better control of an 
intra-rectal SIV challenge than those animals that had no pre-existing vaccinia virus immunity.  
Finally, it may be important to look at levels of CCR5 expression. In light of the presence of 
high level persisting MVA cellular responses, it may be important to determine their CCR5 
expression to determine the infectability of the cells.  CCR5 is one of the co-receptors that HIV 
targets for cell entry and its importance was highlighted by the failure of the STEP trial of an 
Ad5 HIV vaccination regimen.  It was found that CCR5 expressing activated CD4+ T-cells 
were higher in those individuals with high Ad5 antibody titre (McElrath et al., 2008) and that 
these cells could home to the genital mucosa where they presented an increased target for 
HIV entry  (Benlahrech et al., 2009).   Furthermore, these vaccine candidates are in clinical 
trials in humans and it would be interesting to see if anti-vector responses are present, 
whether they are as long-lived as those seen in baboons, and if they have any effect on HIV-
insert specific responses. 
 
In summary, the cellular and humoral responses to HIV antigens expressed by a recombinant 
MVA vaccine vector were boosted even in an environment in which strong cellular and 
humoral responses to the MVA vector were present.   The only successful HIV vaccine trial to 
date used a poxvirus vector (Rerks-Ngarm et al., 2009), and thus, MVA remains a promising 
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